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Curcumin, a herbal polyphenol, has demonstrated anticancer activity in vitro as well as in vivo but 
have limited clinical benefits due to low oral bioavailability. Structural modification such as 
truncation of the β-diketone moiety of curcumin led to the development of the 1,5-diaryl-3-oxo-
1,4-pentadienyl pharmacophore and its importance in displaying antineoplastic properties has been 
demonstrated by our laboratory. In light of this concept, this thesis focuses on the design and 
development of novel 3,5-bis(benzylidene)-1-[3-(arylcarbonylaminoamino)-3-oxo-1-propyl]-4-
piperidones 64a-g having two pharmacophores, namely, the 1,5-diaryl-3-oxo-1,4-pentadienyl 
moiety which is believed to act at the primary binding site and N1-acylhydrazides 60a-m which 
are considered to be the auxiliary binders. 
The biological screening reveals that the auxiliary binders 60m (IC50 = 15.27 µM in HCT 116 
cells) and 60l (IC50 = 3.18 µM in MCF-7 cells) were the most potent cytotoxins in series 60. The 
evaluation of druglike properties revealed that 64a is the lead tumor-specific cytotoxin with an 
IC50 value of 1.38 µM against HCT 116 cells. When compared against colon CRL-1790 non-
malignant cells, these cytotoxic agents (60a, 60m, 63a and 64a-g) and 60j-l showed greater 
selective toxicity towards colon HCT 116 cells and breast MCF-7 cells, respectively. (Tables 5.2, 
5.3 and 5.5). The combinatorial study indicated that 60m is a chemosensitizer towards HCT 116 
cells to 3,5-bis(benzylidene)-4-piperidone 63a and the reference drug 5-fluorouracil (Table 5.8, 
6.2). When screened against various human oral carcinoma and normal cell lines, 63a has shown 
potent cytotoxicity (CC50 < 0.46 µM) and 60a, 60d and 60l showed moderate activity (CC50 in 
range of 46-47 µM) (Table 5.9). Four auxiliary binders 60a, 60d, 60h and 60l displayed excellent 
cytotoxicity in the range of 0.15-5.62 µM when screened against various adherent and non-
adherent leukemic cells (Table 5.10). All four compounds displayed high cytotoxic potency and 
greater selectivity towards Ramos leukemic cells with 60h being the most potent with an IC50 
value of 0.15 µM and 60l being highly selective with a selective index value greater than 90. 
The cytotoxic effects of the auxiliary binder 60l (in Ramos leukemic cells) and target compounds 
64a, 64e and 64g towards HCT 116 cells might be due to decreasing the mitochondrial membrane 
potential and a 2-4 fold increase in the reactive oxygen species levels (60m, 64a, 64e and 64g in 
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CHAPTER 1 : INTRODUCTION 
1.1 Background 
Although there have been many advances in the field of oncology over the years, cancer remains 
a major health issue globally. According to the WHO, 8.8 million deaths were due to cancer in 
2015 and it became the second leading cause of mortality worldwide.1 Cancer not only impacts 
the quality of life but also causes substantial economic burdens to society. Nearly US $113 billion 
was spent globally for cancer treatment in 2016 which is further expected to exceed  US $147 
billion worldwide by 2020.2 In Canada, cancer is a life-threatening disease which is responsible 
for 30% of deaths in contrast to heart diseases (19.7%) and cerebrovascular diseases (5.3%).3 
Recent statistics from the Canadian Cancer Society suggest that approximately 50% of Canadians 
will be diagnosed with cancer and 2 out of 5 of them will die in 2017. It also indicates that the 
majority of cancer patients are over the age of 50 years which significantly lowers their life 
expectancy. The most common types of cancer among Canadians are lung, breast, colorectal and 
prostate cancer accounting for about 50% of the new cases. In Canada, colorectal cancer (CRC) is 
the third most commonly diagnosed cancer (excluding non-melanoma skin cancers) and based on 
the 2017 statistics, CRC accounts for 13% of all new cancer cases.3 
1.2 Cancer 
Cancer is a heterogeneous disease characterized by abnormal, uncontrolled cell multiplication. 
Cancer cells can either be localized resulting in a primary tumor formation or they can spread to 
other parts of the body through the blood or the lymphatic system by metastasis. The main factors 
for abnormal, uncontrolled multiplication include changes in growth factors/receptors, 
intracellular signaling pathways mainly controlling the cell cycle and apoptosis, telomerase 
expression and tumor-related angiogenesis.4,5 
In simple terms, cancer can be classified into four main types which are carcinomas (cancer of 
different body organs), sarcomas (cancers of bones, cartilage, muscles and connective tissue), 
lymphomas (cancer of the lymphatic system) and leukemia (cancer of the blood). Various risk 
factors are linked to the prevalence of cancer. These include, but are not limited to alcohol use, 
smoking, unhealthy diet, physical inactivity and exposure to carcinogens (UV light, radiation, 




virus, hepatitis C virus, and Epstein-Barr virus).1 Age is believed to be another factor contributing 
to cancer. Although the chances are higher in the elderly, children also have cancer. There is a 
significant reduction in cancer mortality rates if it is detected and treated in the early stages of 
development. Based on the type and progression of cancer, different treatment options are 
available such as surgery, radiation therapy, chemotherapy, immunotherapy and hormonal therapy. 
Amongst these options, surgery, and radiation therapy are used for localized treatment whereas 
chemotherapy can also be used for systemic treatment.  
1.2.1 Chemotherapeutic agents 
Cancer is the result of abnormal cell proliferation. Cell multiplication occurs in a cyclic fashion 
wherein reproduction of one cell results in two daughter cells and so on. In a cell cycle, there are 
four stages of cell division namely, G1, S, G2 and M phases. The G1 and G2 phases occur before the 
S and M phases, respectively. The synthesis of genetic material such as DNA occurs in the S phase. 
The M phase is responsible for mitotic cell division and cytokinesis.6  
Different chemotherapeutic agents are classified as either cell-cycle specific or non-cell-cycle 
specific. Cell-cycle specific chemotherapeutic agents are active at a certain stage of the cell-cycle. 
Cell-cycle specific drugs act at one phase in the cell cycle such as antimetabolites which act at the 
synthesis phase. On the other hand, the antineoplastic alkylating agents are non-cell-cycle specific 
and act whether the cells are active or in the resting stage.7 They can also be classified according 
to their mechanisms of action, their chemical structures and their relationship to other drugs. For 
example, anticancer drugs may be classified as alkylating agents (carmustine, busulfan), anti-
metabolites (methotrexate, 5-fluorouracil), plant derivatives (vinca alkaloids, taxanes, 
camptothecin), cytotoxic antibiotics (doxorubicin), hormones (steroids such as estrogens and 
androgens) and miscellaneous agents (asparaginase).  
Chemotherapy is given with the aims to either cure the cancer or to control the disease or as 
palliation to relieve symptoms when cancer is at an advanced stage. Most chemotherapeutic agents 
are effective during the logarithmic growth of tumors. However, with an increase in the size of a 
tumor, their efficacy decreases. This problem can be solved if the tumor is removed by surgery or 
radiation therapy is used along with chemotherapy.  The success rate is highly dependent on the 




1.3 New paradigms in cancer treatment 
Since the last decade, our perspective towards cancer and its treatment have changed considerably. 
Chemotherapy has been used for many years; however the problem of drug resistance and toxicity 
persists. The identification of various drug resistance proteins and their biochemical pathways have 
been successful with the help of various biomarkers in vivo. Recently, the concept of tailored drug 
therapy has come into the picture. Novel drugs have been designed and developed according to 
the genetic make-up of the individual. These therapeutics are designed with a “personalized” 
approach (right medication for the right person given at the right time with the right dose) instead 
of the traditional ones with “one size fits all”.8,9 Newer treatment options like biomarker-based 
patient segmentation and other diagnostic approaches have been added to the treatment regimen.   
1.3.1 Cancer biomarkers 
Genetic materials such as DNA and RNA, proteins, peptides, metabolites, and hormones are 
believed to be potential indicators of cancer. Moreover, biological processes such as apoptosis, 
angiogenesis or proliferation are also considered to be diagnostic markers. These biomarkers are 
specifically derived from neoplasms and isolated non-invasively and can be detected either in the 
circulatory fluids (blood, serum, plasma) or secretory fluids (urine, stools or sputum). The 
carcinoembryonic antigen (CEA) and epidermal growth factor receptor (EGFR) are cancer 
biomarkers used for monitoring and prediction of colorectal cancer.9  
1.3.1.1 Circulating tumor cells (CTCs)  
Circulating tumor cells were first noticed by an Australian pathologist in the late 18th century. He 
observed circulating cells in the autopsy of a metastatic tumor and concluded that these cells were 
isolated from a tumor network and became a part of the circulatory system. CTCs are considered 
as a “liquid biopsy” as they detach from the tumor and circulate either in the blood or the lymphatic 
system. CTCs are one of the unique emerging biomarkers gaining attention in recent years for the 
detection of neoplasms in patients. CellSearch® Test was clinically approved by the FDA in 2007 
and is used for early prognosis in a patient. 
When isolated, the phenotypic and genotypic properties of CTCs can provide a significant amount 
of information regarding the tumor cells propagation and metastasis biology. Their molecular 




proteins MRP1, MRP2, MRP4, MRP5, and MRP7 have been found in CTCs. These can provide 
useful information for the elucidation of downstream pathways and their mechanisms of action. 
CTCs serve as viable tools for the isolation, detection, and prognosis of the disease.9,10,11 For 
example, nuclear PD-L1 was believed to be a molecular diagnostic marker in patients with CRCs 
in stage IV, and prostate cancer stage VI while the survival was less in patients with expression of 
nPD-L1.12 
1.3.1.2 Angiogenesis 
Angiogenesis is a crucial process of forming new blood vessels from pre-existing ones which are 
essential for the primary growth of the tumor, invasion, and metastasis13 and therefore it is a vital 
and appealing target for therapeutic intervention. Tumors with a size of 1-2 mm receive a supply 
of oxygen and nutrients by simple diffusion. For the further progression of the tumor, malignant 
cells secrete growth factors which are responsible for forming new blood capillaries by activating 
endothelial cells14 and finally infiltrate the tumor mass.15  
A rapidly expanding endothelial surface allows tumor cells to enter the circulation and metastasize 
whereas the release of anti-angiogenic factors explains the control exerted by primary tumors over 
metastasis. This indicates that a balance between pro-angiogenic and anti-angiogenic growth 
factors and cytokines markedly control angiogenesis.15 Tumor angiogenesis results by increased 
secretion of angiogenic factors and/or down-regulation of angiogenesis inhibitors.16 Several 
proangiogenic molecules such as the vascular endothelial cell growth factor (VEGF), which is 
highly specific for endothelial cells, the fibroblast growth factors (FGFs), the matrix 
metalloproteinases (MMPs), methionine aminopeptidase-2 (MetAP-2), tubulin, cyclooxygenase-
2 (COX-2), angiopoietins and the angiogenesis inhibitors such as platelet factor-4, angiostatin, 
endostatin, and vasostatin are involved in the regulation and control of the angiogenic process. 
Inhibition of angiogenesis can prevent diseases such as cancer, diabetic nephropathy, arthritis and 
psoriasis.15,17 Approaches to novel anti-neoplastic therapy include targeting the growth signal 
transduction within cancer cells i.e., the mechanisms involved in cell invasion and metastatic 
spread, apoptosis and the cell cycle, and tumor-related angiogenesis. Molecularly targeted 
anticancer therapies like small-molecule tyrosine kinase inhibitors (TKIs) and monoclonal 
antibodies have been successfully introduced to treat patients with various cancers including breast 




tumor (GIST)13. One of the most promising targeted therapies to treat cancer is the addition of 
antiangiogenic therapy to the therapeutic regimen. The real potential of antiangiogenic agents for 
cancer therapy resides in strategic combinations with treatment modalities such as chemotherapy, 
radiation, and tumor-targeting agents such as radioimmunotherapy.18 Colon cancer requires 
angiogenesis for progression and metastasis and thus inhibition of angiogenesis can be a promising 
target for colon cancer therapy.19  
1.3.2 Antibody based immunotherapy 
The targeting of immune cells rather than cancer cells is one of the emerging strategies available 
along with conventional treatment. Antibodies are designed in such a way that they target the 
surface antigen expressed on the tumor cells and induce cell death through processes known as 
antibody-dependent cell-mediated cytotoxicity (ADCC). These immunomodulatory antibodies 
either activate immune-stimuli responses or antagonize immunosuppressive pathways.20  
Many FDA approved immunomodulatory antibodies are available in the market which are used 
therapeutically to activate antineoplastic immune responses. The epithelial growth factor receptor 
(EGFR) is a tyrosine kinase receptor which is overexpressed in colon cancer. Cetuximab and 
panitumumab are specific EFGR antibodies used to treat metastatic colorectal cancer (mCRC)20,21 
in combination with 5-FU as an adjuvant chemotherapeutic agent. They inhibit EGFR signalling 
and thus prevent receptor dimerization resulting in the cell death in tumor cells. Human epidermal 
growth factor receptor 2 (HER-2) is overexpressed in breast cancer. Trastuzumab was the first 
anti-HER2 antibody, approved by FDA in 2006 for treatment of HER2+ breast cancer along with 
chemotherapy. Pertuzumab was recently approved in 2017 and used along with chemotherapy as 
adjuvant treatment. Even though they are clinically proven immunomodulators, their use in 








1.4 Current challenges in cancer chemotherapy 
Cancer is one of the prime causes of premature death even though there are so many developments 
in drug discovery and numerous chemotherapeutic agents available in the market. One of the main 
reasons for this is that chemotherapeutic agents attack the rapidly growing cancerous cells as well 
as fast-growing healthy cells (bone marrow/blood cells, cells of the hair follicles, cells lining the 
digestive and reproductive tracts). Thus toxicity and severe side effects are involved with the use 
of chemotherapy drugs. The quest to minimize these side effects has always been of much interest 
to researchers.  
 
Figure 1.1 : Representation of factors responsible for chemotherapy failure and newer 
approaches to treat cancer. 
Targeted and smart drug therapy to one or more specific sites of action seeks to treat cancer more 
efficiently because of the greater understanding of the molecular changes involved in cancer 
progression. These drugs target specific molecules involved in tumor growth and usually have less 
severe side effects than chemotherapy drugs and greater drug uptake as well as increased patient 
compliance.  
Another hurdle with the use of chemotherapy is the problem of drug resistance. Resistance can be 
natural or acquired. Natural resistance is observed when a tumor is not responsive towards drug 
therapy probably because the malignant cells are in a plateau growth phase with less growth 




effective to neoplasms but later fail to show responsiveness because of a number of mechanisms.7 
When tumors are treated with chemotherapeutics, malignant cells are killed and tumor size 
decreases. However, resistant clones develop on continuous exposure to chemotherapeutic drugs, 
and their division leads to the rebuilding of the tumor network by constant multiplication. Thus 
the chemotherapy is no longer as efficacious as it was previously. Resistance can be developed by 
a number of mechanisms such as intracellular inactivation or metabolic bypass of the drug before 
reaching the target, alteration of the target site to avoid binding and low cell permeability which 
impairs the influx/efflux of drug.22  
Multidrug resistance (MDR) is problematic as resistance develops not only against a single agent 
but also against other drugs that fall into the same class. Mechanistic investigations show the role 
of membrane transporter proteins. P-glycoprotein (P-gp) is the efflux protein belonging to the ABC 
superfamily of transporters and is encoded by the MDR1 gene. Drugs are less effective as its 
intracellular concentration is significantly reduced because of increased activity of the energy-
dependent efflux pump which is a result of overexpression of P-gp. Various drugs belonging to 
the class of calcium channel blockers, antiarrhythmics and cyclosporine A analogues modulate P-
gp in vitro but limited efficacy is seen clinically.7 
The p53 gene is the first tumor suppressor gene discovered by scientists and research reveals that 
the p53 pathway is significantly altered in cancer cells. In cancer cells under stress conditions and 
DNA impairment, p53 is activated and downregulated to induce cell cycle arrest, apoptosis, DNA 
repair and inhibition of angiogenesis. The mutation of p53 is unable to induce apoptosis in the 
cells and may finally lead to uncontrolled cell multiplication. Over 75% of its mutations are the 
result of a single amino substitution making it genetically unstable and thus favouring a tumor 
initiation environment. Overexpression of the MDM2 gene is responsible for p53 inactivation.6 
Anticancer drugs have been developed with the aim to target enzymes or biological processes, 
such as tyrosine kinase inhibitors which use p53 as an anti-cancer agent, angiogenesis and 
metalloproteinase inhibitors, cyclooxygenase inhibitors, antisense oligonucleotides, reverse 
multidrug resistance drugs as well as gene therapy. There is a great need to understand the potential 
mechanisms of action of resistant proteins and an urgency to develop new novel chemotherapeutic 




1.5 Chemosensitivity of tumors to antineoplastic agents 
As mentioned earlier, various mechanisms are responsible for the failure of chemotherapeutic 
agents. However the concept of chemosensitivity came to light as one of the efforts to overcome 
the problems of drug resistance and drug toxicity. The basic principle of chemosensitization is that 
tumors are sensitized to anticancer agents which potentiates the efficacy of the latter in cancer 
treatment. This process can also result in a dose reduction of the anticancer agent when tumors 
have already been treated by chemosensitizers. Chemosensitizers can either be drugs, synthetic 
organic compounds, natural products, modulators of thiol concentration or miscellaneous 
compounds. Figure 1.2 depicts an approach to chemosensitize a neoplasm prior to antineoplastic 
drug treatment.  
 
Figure 1.2 : Representation of the effect of a chemosensitizer to a tumor prior to antineoplastic 
drug treatment. 
One of the main advantages in using an existing drug as a chemostimulant is the awareness of its 
pharmacokinetic profile and established pharmacodynamic effects. Synergistic effects can be seen 
when either the drugs having similar mechanisms of action or are acting on different targets. 
However, the latter is considered more fruitful particularly in the case of MDR. 
 
As an example, ethacrynic acid 1 having an α,β-unsaturated keto group interacts with the thiol 
groups in the renal tubules and sensitizes malignant cells to cytotoxins. Series 2 are derivatives of 




acceptors. Compound 2a is highly cytotoxic towards human SK-MEL19 and SK-MEL23 
melanoma cells. Synergism is observed when compound 2 is administered in the presence of 
compound 1. The high reactivity of cinnamaldehyde and its lipophilicity contributed towards its 
cytotoxicity.23 
As discussed earlier, cellular membrane proteins like P-gp act as efflux pumps and thereby they 
decrease the intracellular drug concentration. Inhibition of P-gp as seen in Figure 1.3, by a 
chemosensitizer can be one of the ways to prevent MDR.  
 
Figure 1.3 : Effect of P-gp expression in the presence of a chemosensitizer. 
 
As an example, verapamil 3 is a calcium channel blocker, mainly used to treat hypertension and 
angina. It plays a crucial role in the inhibition of the activity of P-gp. Verapamil 3 increased 
cytotoxicity and induced apoptosis by sensitizing the proteasome inhibitors MG132, bortezomib 
and carfilzomib towards MDA-MB-231 TNBC. Increased cytotoxicity was observed when 
nicardipine, a P-gp inhibitor, was combined with bortezomib or carfilzomib.24 
Rhamnetin 4 is a natural flavanol which can be isolated from clove. Recent studies showed that 
rhamnetin was a potential sensitizer of hepatocellular carcinoma (HCC) cells to paclitaxel, 
etoposide and sorafenib. The Notch-1 pathway upregulation in cancer cells is responsible for 




of the Notch-1 pathway was seen thereby resulting in reducing MDR and there was a marked 
reduction in the expression of MDR-related proteins like P-gp and BCRP in HepG2/ADR cells.25 
There are several mechanisms identified through which tumors are sensitized. Chemosensitization 
influences various cellular processes at the mitotic stage by inhibiting tubulin polymerization26 as 
well as modulating genes involved in the cell-cycle. They potentiate the activity of protein kinase 
enzymes27 and transcription factors, control ROS levels in tumor cells28,29, causes apoptosis by 
PARP cleavage26, change levels of cellular thiols or by inhibition of GSTs.30 The use of 
chemosensitizers is an encouraging approach accounting for MDR reversal, toxicity reduction by 
decreased dose intake as well as selectivity towards cancer cells rather than normal cells.  
1.6 Importance of conjugated α,β-unsaturated carbonyl compounds in chemotherapy 
Compounds possessing an α,β-unsaturated carbonyl moiety are highly reactive as they are 
considered to be a Michael acceptor for cellular nucleophiles.31 Many natural products such as 
chalcones, curcumin and coumarin contain an α,β-unsaturated carbonyl group and display a 
number of biological activities including anticancer, antioxidant, anti-inflammatory, antimicrobial, 
antiprotozoal, antiulcer, antihistaminic and multidrug resistance reversal properties.  
Chalcones (1,3-diaryl-2-propen-1-ones) emerged as ‘magic bullets’ due to their selectivity towards 
cancer cells without affecting normal cells.32 Clinical trials have shown that these compounds 
reached reasonable plasma concentrations and are well-tolerated.33 Four groups of bioactive 
compounds which possess the α,β-unsaturated keto group are 1,3-diaryl-prop-2-en-1-ones 
(chalcones), 1,5-diaryl-3-oxo-1,4-pentadienes, 1,5-diaryl-pent-1en-3-ones and 1,7-diaryl-hept-3-
en-5-ones (Figure 1.4).34  
Over the years, our lab has focused on developing and synthesizing various α,β-unsaturated keto 
derivatives as cytotoxic alkylating agents based on the following important considerations. (1) 
These agents have a distinct affinity towards thiols rather than amino or hydroxyl groups. This 
specificity is useful to avoid toxic affects that arise from the interaction of anticancer drugs with 
genetic material.35 (2) Elevated thiols levels are usually noted in malignant cells36 as compared to 
normal cells. These compounds decrease thiol concentrations and may significantly impair various 
regulatory processes including MDR by sensitization of malignant cells to antineoplastic agents. 
(3) These agents can be cell cycle specific interfering with the mitotic phase of cell division during 




MDR-revertant properties.  
Thus new paradigms are emerging to synthesize novel α,β unsaturated ketones for selective 
toxicity to malignant cells and for treatment of MDR tumors.  
 
 
Figure 1.4 : Reactivities and important series of α,β-unsaturated carbonyl compounds. 
1.7 Novel curcumin-based cytotoxic agents 
Curcumin, a polyphenol, obtained from Curcuma longa L., has been traditionally used as a spice 
in cooking. It has been used conventionally as a carminative, laxative, for stomach pain and as a 




antiinflammatory, antibacterial, antiviral, antifungal, antiparasitic and antispasmodic 
properties.38,39 Another advantage of curcumin is that it is safe and effective and probably shows 
no or less toxicity than chemotherapeutic agents. The keto form of curcumin is symmetrical in 
structure with two aryl methoxy and two hydroxy groups linked by diendione moiety.   
Curcumin [1,7 bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadien-3,5-dione] has been extensively 
explored for its anticarcinogenic characteristics in the colon, gastric tract, ovary, prostate and 
lymph.37 Recent studies involve the use of curcumin as a potential candidate to treat 
hyperlipidemia40, obesity40, multiple sclerosis41 and systemic lupus erythematosus.42 One of the 
studies highlights that curcumin can serve as a future target for Zika and Chikungunya viruses by 
inhibiting their replication processes.43 However curcumin is considered a poor lead compound 
despite its clinical benefits, because of its poor pharmacokinetic and pharmacodynamic profiles. 
The phenolic -OH groups in curcumin undergo phase II transformation into glucuronides and 
sulfates by transferases in vivo resulting in a rapid elimination of water soluble metabolites44,45,46 
and shorter half-life of 6-7 h.47 Low solubility and bioavailability, aqueous instability and 
extensive metabolism have restricted its therapeutic use.  
Figure 1.5 : Tautomerism of curcumin. 
NMR studies detected only the enolate form 5b in solvents. The enol form 5b is believed to be 
more stable because of intramolecular hydrogen bonding. Curcumin undergoes chemical 
degradation in alkaline pH, autooxidation and photodegradation to break into various moieties 
including vanillin, ferulic acid, bicyclopentadione and ferulic aldehyde.48 To solve this problem, 
different formulation approaches have been employed such as nanoparticles, nanocrystals, 
emulsions and liposomes to make curcumin more stable in vivo. 
In recent years, several strategies have been pursued by researchers to make structural 
modifications in curcumin by the addition of functional groups to increase the potency and efficacy 
at the therapeutic level. Figure 1.6 highlights a few of the approaches to overcome the 





Figure 1.6 : Molecular modifications of curcumin. 
Two different curcumin analogues were synthesized with the addition of an ester and acid groups 
at carbon atom 4 of curcumin to give rise to 6 and 7. Addition of the alkyl chain at C-4 position in 
6 and 7 increased the stability in vitro resulting in greater cytotoxicity than curcumin. 
 
The presence of a Boc functional group in 6 kept the curcumin backbone intact with no degradation 
and was highly lipophilic as compared to 7 accounting for its faster cellular uptake and selectivity 




stabilizes keto-enol tautomerism. The presence of phenolic OH groups on the aromatic rings 
contributes to the antioxidant activity of compounds 6 and 7.37 
 
Another study outlined the conversion of 2-hexadecynoic acid to a C5-curcumin. C5-Curcumin 8 
is formed by the removal of the β-diketone moiety. It was found to be active against various strains 
of bacteria such as E. coli and S. aureus. C5-curcumin-2-hexadecynoic acid 9 was synthesized and 
it was found to be active towards multidrug resistant bacterial strains like methicillin resistant 
Staphylococcus aureus (MRSA) with a minimum inhibitory concentration between 31.3-62.5 
µg/ml. It was noted that the presence of a triple bond at the C-2 position in 2-hexadecynoic acid 
resulted in 4-8-fold higher anti-bacterial activity. Compound 9 was also found to restrict the 
supercoiling activity of DNA gyrase and inhibited DNA topoisomerase which alters various 
replication, recombination and transcription processes. A similar study was carried out previously 
by one of the research groups wherein palmitic acid was conjugated with curcumin.  Addition of 
palmitic acid was advantageous as the ester bonds in Curcumin-PA conjugate were hydrolyzed by  
carboesterases resulting in a decreased rate of metabolism of curcumin.49 
Quaternary piperazine curcuminoids were developed to improve the physicochemical properties 
of curcumin. These curcuminoids were synthesized by the Baylis-Hillman (BH) reaction wherein 
BH derived allyl bromides were first synthesized which are highly reactive electrophiles and may 
interact with molecules like DNA, GSH or cysteine. These quaternary ammonium curcumin 





Compound 10 was cytotoxic against human triple negative breast cancer MDA-MB-231, 
metastatic murine breast cancer 4T1 and human pancreatic cancer MIAPaCa-2. In vivo toxicity 
studies of compound 10 suggested that it was well tolerated in mice with no significant changes in 
body weight or stress conditions. Furthermore compound 10 was used in vivo to treat pancreatic 
tumors by passaging MIAPaCa-2 cells in nude mice. Compound 10 inhibited tumor growth by 
42%  while gemcitabine inhibited the tumor growth by 47% .50 
 
To improve the pharmacokinetic stability of curcumin, the β-diketone moiety was replaced by a 
single carbonyl group. Such monocarbonyl curcumin analogues (MACs) having electron-
withdrawing substituents are thought to display greater cytotoxicity than curcumin. Moreover, para 
substitution in these analogues serves as secondary binding sites of the target molecules. 
Compounds 11a, 12a and 12b showed apoptosis in gastric cancer cells SGC-7901. All three 
compounds induced apoptosis by downregulating capase-3 and Bcl-2 expression and upregulating 
cleaved PARP expression. Compound 12a displayed greater activity as compared to the others and 
showed 48% tumor efficacy in vivo.51 
Novel bis(hydroxymethyl) alkanoate analogues of curcumin were designed as potential anti-cancer 
agents. Compound 13 was synthesized by esterification of both phenolic -OH groups and 
incorporation of bulky groups onto the aliphatic hydroxyl group. This strategy resulted in better 
solubility than curcumin. The logP value of compound 13 was found to be 1.73 as compared to 
3.38 for curcumin. Compound 13 was 6.1 times more potent in MDA-MB-231 breast cancer cells 
than curcumin. If the methyl group was substituted by an ethyl group then a slight decrease in the 





The important difference between compound 13 and 14 was tautomerism. Compound 13 existed 
in convertible enol and keto forms with the enol form considered to be the most stable whereas 
compound 14 is in the keto form and is not able to tautomerize because of the additional methyl 
groups restricting its conformation. The IC50 values of compounds 13, 14 and curcumin towards 
MDA-MB-231 cells was found to be 1.98 µM, 2.67 µM and 16.23 µM, respectively. When 
doxorubicin was used in combination with compound 13, synergism was observed in vitro as well 
as in vivo. Compound 13 resulted in apoptosis by cell cycle arrest in the G2/M phase. It is a potential 
antioxidant as it leads to the expression of the heme oxygenase 1 enzyme in MDA-MB-231 cells. 
Because of lower toxicity in vivo, it could be a potential drug for treating triple negative breast 
cancer.52 
Another study found that a C5-curcumin conjugated with fatty acids to form C5-curcumin-fatty 
acid (C5-Curc-FA). Conjugates possessing decanoic acid or palmitic acid were found to be more 
cytotoxic against colorectal adenocarcinoma CCL-229 cells than curcumin. Moreover structure-
activity relationships revealed that decanoic acid in the meta position is essential for antineoplastic 
activity. 
 
It was also noted that anticancer potencies were greatly influenced by the number of carbon atoms 
in the fatty acid chain. Cytotoxicity was increased with a decrease in the number of carbon atoms 
in the fatty acids. Nuclear factor kappa B (NF-κB) plays a crucial role in inflammation signalling 
as well as apoptosis. Compound 15 inhibits the activity of NF-κB probably because of its 
favourable lipophilicity. Furthermore various bioassays revealed some of the possible mechanisms 
of cell death of these conjugates. Compound 15 induces apoptosis, decreased MMP (caused 68 % 




nuclear expression. Compound 15 is 5-10-fold more effective for inhibiting DNA topoisomerase 
I as compared to compound 16 due to the presence of the fatty acid group at the meta position.53 
 
Substitution in the aromatic ring of a curcuminoid with a fluoro group was undertaken to evaluate 
their efficacy towards lung cancer. Analogues designed with fluoro substituents have contributed 
towards greater binding capacities and pharmacokinetic stability. Compound 17a was found to be 
4 times more cytotoxic than curcumin towards lung NCI-H460 cancer cells. The relative 
cytotoxicity can be represented as 17a > 17b > 17c. The analogue with an ortho substituent was 
highly toxic to NCI H460 cells as compared to compounds possessing meta and para substituents. 
Fluoro substitution may have stabilized the molecule and as a result more cellular uptake was 
observed in NCI-H460 cells as compared to curcumin. Dose-dependent apoptosis was induced by 
17a which in turn was corelated with an increase in the generation of reactive oxygen species 
(ROS). This possible mechanism of cell death was confirmed by a decrease in the mitochondrial 






MC37 is a novel analogue of curcumin with fluorine as a key substituent. Compound 18 was 
cytotoxic towards colon cancer cells and impeded the cell-cycle at the G2/M phase. The average 
IC50 values of 18 and curcumin towards colon carcinoma cells (HCT-8 and SW480) were 0.34 µM 
and 12.36 µM, respectively. Further possible mechanisms of cytotoxicity were investigated and 
the findings revealed that collapsed mitochondrial membrane potential, activation of capases-3 and 
caspases-9, upregulated Bax/Bcl-2 ratio and downregulated cyclin dependent kinase 1 (CDK1) 





In a recent reference, curcumin analogues were synthesized with the incorporation of acrylate 
functional group in curcumin. Curcumin multiacrylate species were developed by alkylating the 
three hydroxy groups in curcumin with acryloyl chloride to obtain mono-, di- or triacrylate 
derivatives. The ratio of curcumin : acryloyl chloride plays an important role to form the 
corresponding derivatives. Various techniques such as HPLC, LCMS and NMR were used to 
characterize different curcumin based multiacrylate moieties.54 Previous studies highlighted the 
use of curcumin acrylation to improve the stability as well as solubility by formulating hydrogels55 
and microspheres.56 
1.8 Development of 1,5-diaryl-3-oxo-1,4-pentadienes as potential cytotoxic agents 
Over the past few years, various approaches have been made to incorporate additional functional 
groups to compounds possessing the 1,5-diaryl-3-oxo-1,4-pentadienyl group with the following 
objectives. (1) It is well known that the possibility of drug resistance increases if the drug 
continuously binds to only one active site. This problem can be overcome if the drug candidate 
has more than one potential active binding sites which interacts with cellular moieties. Thus the 
efficacy of a drug can be increased. (2) A drug candidate with different potential interactive sites 
may undergo extensive metabolism in such a way that it is removed from the body resulting in low 
or no chances of toxicity. (3) It is more fruitful to use a single drug acting on many targets rather 
than using several drugs for various targets.  Multitargeted drugs may work through different 
biochemical pathways and may also have pharmacological effects to treat comorbid conditions. 
This approach may reduce the side effects associated with using several drugs at the same time. 
To design novel cytotoxic agents, researchers mounted the 1,5-diaryl-3-oxo-1,4-pentadienyl group 
onto several scaffolds such as piperidones, cycloalkanones and 2-tetralones and significant 





Figure 1.7 : The incorporation of the 1,5-diaryl-3-oxo-1,4-pentadienyl pharmacophore to form 
potential cytotoxic agents. 
As mentioned earlier, various chemotherapeutic agents used in cancer treatment exhibited effects 
on both neoplasms as well as normal cells. This results in various side effects associated with these 
agents. Thus there was a need to develop antineoplastic agents which are selectively toxic towards 
malignant cells and not non-malignant cells. Hence the theory of sequential toxicity came into the 
picture. It was proposed that successive chemical attacks could damage cancer cells to a greater 
extent as compared to normal cells. For example, as indicated in Figure 1.8, intracellular thiols can 
interact at position 1 of the 1,5-diaryl-3-oxo-1,4-pentadienyl pharmacophore. Subsequently thiols 
can bind at position 5. If the neoplasms are damaged more than the normal cells with the initial 
chemical insult, then chemosensitization of the tumors will have occurred. A second interaction 
with a cytotoxin may lead to tumor-selective cytotoxicity.57   
 





1.8.1 Mannich bases 
Over the years, our lab’s research work has focused on Mannich bases. Dr. Dimmock and his team 
have contributed significantly towards the design and synthesis of Mannich bases and their role in 
cancer treatment. A Mannich reaction is the condensation between a compound having a labile 
hydrogen atom next to a carbonyl function, an aldehyde (generally formaldehyde) and a primary 
or secondary amine or ammonia. 
 
Scheme 1.1 : A Mannich reaction between a substrate, formaldehyde and secondary amine. 
Mannich bases have various pharmacological activities including antiinflammatory, antibacterial, 
antifungal, anticonvulsant, antitubercular, analgesic, anti-HIV, antimalarial, antiviral and 
anticancer properties. Mannich bases inhibit various endogenous enzymes such as cholinesterase, 
α-glucosidase and purine nucleoside phosphorylase that play key roles in the regulation of 
molecular processes. Previous research work from our lab have revealed that Mannich bases as 
well as the α,β-unsaturated keto moiety contribute towards the cytotoxicity of neoplasms as 
hypothesized by the sequential cytotoxicity theory.35 
1.8.2 Acyclic Mannich bases 
Dimmock et al synthesized a series of acyclic Mannich bases or β-aminoketones which had either 
one or two centres for nucleophilic attack by cellular constituents. Compounds 20 and 21 were 
evaluated against the WiDr colon cancer and their IC50 values were found to be 0.8 µM
58 and 0.45 







CDDP 22 is an acyclic Mannich base which inhibited various isoenzymes of GST. This compound 
was synthesized with the hypothesis that if a tumor having a lower level of α-GST isoenzyme than 
normal cells and the alkylating agent has a selectivity towards this isoenzyme, then a second 
chemical insult may be more damaging to tumors as compared to normal cells having higher 
concentrations of α-GST.60 Compound 23 inhibits the growth of WiDr colon cancer with an IC50 
value of 2 µM and was found to be less toxic towards human CRL-2522 fibroblasts. Compound 
23 is a lead compound with greater potency than cisplatin.61 Some of the Mannich bases obtained 
from 1-aryl-4-methyl-1-penten-3-ones showed greater cytotoxic potency than the precursor 
ketones towards murine P388 and L1210 leukemic cells and human tumor cell lines. Some 
Mannich  bases are effective in treating drug resistant tumors.62 
1.8.3 Cyclic Mannich bases 
1.8.3.1 3,5-bis(Benzylidene)-4-piperidones 
Although the Mannich bases 24 are highly cytotoxic, they caused respiratory depression in mice. 
Hence, structural modifications were made by adding a second benzylidene group as a potential 
alkylating site while retaining the arylidene keto and carbonyl functionality. This approach reduced 
the flexibility and restricted the conformation of the molecules as compared to 24.  Compound 25a 
is a lead compound developed by Dimmock and coworkers and has 5800 times greater cytotoxic 
potency than the anticancer drug BCNU towards P388D1 leukemic cells.63 
 




3,5-bis(Benzylidene)-4-piperidone 25a is a thiol alkylating agent as it interacts with cellular thiols 
by lowering the hepatic glutathione levels in mice and is well tolerated in mice (with a daily dose 
of 240 mg/day for 5 consecutive days). It is highly cytotoxic against murine P388D1 leukemic 
cells in vitro with an IC50 value of 16 pM but was inactive in vivo. It  is believed that due to poor 
pharmacokinetic parameters, its penetration and transport across membranes was difficult.63 Hence 
to overcome this problem, many analogues of 3,5-bis(benzylidene)-4-piperidone were synthesized 
and evaluated with the aims to improve permeability, higher selectivity towards neoplasms and 
effectiveness against MDR tumors. Molecular descriptors like Hammett σ (electronic parameter), 
Hansch π (solubility parameter), molecular refractivity (steric parameter) of substituents, partition 
coefficients (solubility parameter), dipole moment, molecular geometry were taken into 
consideration in the design and development of 3,5-bis(benzylidene)-4-piperidone analogues.  
Compounds 25a-d displayed cytotoxic potency towards human Molt4/C8 and CEM T-
lymphocytes, murine P388 leukemic cells as well as murine L1210 neoplasms.64 In addition, these 
compounds showed greater toxicity to malignant cells (human HSC-2 and HSC-4 squamous cell 
carcinomas and human HL-60 promyelocytic leukemic cells) than non-malignant cells (human 
HGF gingival fibroblasts, HPC pulp cells and HPLF periodontal ligament fibroblasts). The 
selective index values of 25a-d are 10, 4.3, 13 and 29, respectively, suggesting that they are highly 
tumor-selective cytotoxins.65 Incorporation of the electron-donating dimethylamino group in 25h 
(IC50 = 36.4 μM) displayed 15-fold less potency than the unsubstituted 25a (2.5 μM), which is the 
parent compound, in L1210 cells. This effect may be due to a reduction in the positive charge on 
olefinic carbon atoms.66 
 
Apart from being cytotoxic agents, compound 25a-c display antimycobacterial activity with 
minimum inhibitory concentrations of 3.13 μM, 6.25 μM and 0.2 μM respectively. These 




tolerated in a short term toxicity evaluation in mice which means these analogues may be 
promising agents for the treatment of tuberculosis.67 Moreover, 25a-d show potent antimalarial 
activity against drug sensitive D6 as well as drug resistant C235 strains of Plasmodium 
falciparum.68 
Compound 25g, EF 24 is a novel curcumin analogue possessing a fluoro group at the ortho position 
of the aryl rings and exhibited remarkable potency as compared to cisplatin. It was 23.3 and 9.8-
fold more efficacious than cisplatin and curcumin, respectively, against a panel of tumor cell lines 
screened by the NCI in vitro. EF 24 was highly cytotoxic as compared to the antiangiogenic drug 
TNP-470. Further in vivo investigation revealed that it greatly reduced the size of a breast tumor 
in female nude mice.69 The possible mechanism of cell death includes redox-dependent apoptosis 
and cell-cycle arrest in MDA-MB-231 human breast cancer cells and DU-145 human prostate 
cancer cells.70 Further investigations revealed that it can also disrupt the microtubule 
cytoskeleton71 and suppress NF-κB pathways in cholangiocarcinoma (CCA) cells.72 EF 24 also 
acts as antibacterial agent against E.coli and S. aureus.73 
 
Compound 26a shows potency against number of cancer cell lines with average IC50 of 4.69 μM.
57 
Compound 25a exhibits 57-fold higher potency than the N-methyl adduct 26a. 3,5-
bis(dihydroxyborinyl-benzylidene)-1-methyl-4-piperidone 26b showed high cytotoxicity against 
colon HCT 116 cancer cells which were p53 sensitive (HCT 116 p53 +/+) as compared to the ones 
which lacked p53 (HCT 116 p53 -/-). This compound was also cytotoxic against breast cancer cells 
with an IC50 value of 3.5 μM towards MCF-7 and MDA-MB-231 cells
74. A recent study shows 
that compounds 26c and 26d are not only potent cytotoxic agents but also have multidrug resistant 




against a panel of cancer cells as compared to normal human umbilical vein endothelial cells 
(HUVEC). Such compounds displaying dual effects are promising lead molecules.34 
Novel dissymmetrical compounds 26e-h having aryl 3,4-dimethoxy and 3,4,5-trimethoxy groups 
or electron withdrawing groups 2-F, 4-CN, 3-NO2 and 4-CF3 inhibit the growth of HepG-2 and 
THP-1 cells in-vitro and exhibited low cytotoxicity towards normal LO2 cells. The fluoro 
substituted compound 26e is the most potent compound towards HepG-2 cells and exhibits dose-
dependent apoptosis by up-regulating BAX expression and down-regulating Bcl-2 expression. A 
further in vivo investigation showed that compound 26e is well tolerated and supresses the growth 
of  the HepG2 tumor in mice.75 
Another study was undertaken with compounds 27a-c which possess the dual properties of 
cytotoxicity as well as MDR reverting properties. They have anti-proliferative activity against a 
panel of cancer cell lines among which Hela, K562 and U87 cancer cells are the most sensitive. 
The compounds possessing a trifluoromethyl group in the aryl ring were the most cytotoxic 
probably because the nucleophilic attack by cellular thiols is easier as electron-withdrawing groups 
reduce the electron density on the olefinic carbon atoms. 
 
All compounds were selective towards cancer cells as compared to HUVEC normal cells. The 
selectivity of compound 27b is 39 which is noteworthy and merits further considerations. 
Compounds 26c and 27a-c with a trifluoromethyl group and compounds with a 3-bromo 
substitution (26d, 27d-f) decrease the expression level of the resistant gene MDR1 by 11-38% and 
31-46% respectively. Thus compounds 26c and 26d displayed strong potency and more MDR 





A recent study revealed that the incorporation of hydroxyl groups and substitution by 
alkylaminoalkyl groups in the aryl rings may reduce the lipophilicity of compound 25a. 
Physicochemical parameters such as torsion angles between the aryl rings and adjacent olefinic 
groups and logP values had a significant impact on cytotoxicity. When another 
dimethylaminomethyl group was introduced into compound 28 it displays remarkably decreased 
cytotoxicity (IC50  > 500 µM) towards Molt 4/C8, CEM and L1210 leukemic cells. Compound 28 
was highly cytotoxic against a subpanel of human colon cells (COLO205, HCC-2998, HCT 116, 
HCT 15, HT29, KM12, SW-620) with average IC50, TGI and CC50 value of 1.26 µM, 3.09 µM, 
7.25 µM respectively; while for 5-FU the average IC50, TGI and CC50 values are 14.8 µM, >1862 
µM, >2512 µM, respectively. 3,5-bis(3-Dimethylaminomethyl-4-hydroxybenzylidene)-4-
piperidone trihydrochloride 28 is a promising lead antineoplastic agent and its mode of action was 
investigated and shown to cause apoptosis, DNA fragmentation and cleavage of PARP1 in HSC-
2 and HL-60 cells.76 
 
Compound 29 was synthesized in our lab based on the hypothesis that auxiliary binders on the 
arylidene benzene ring will be more potent than the corresponding N-methyl substituted 4-
piperidones. Compound 29 emerged as a lead compound with high potency towards a panel of 
cancer cell lines such as leukemia, lymphoma, prostate, colon, and breast cancers. It was more 
potent than curcumin and EF 24 which is a curcumin analogue. It remarkably inhibited the growth 
in Ramos, RAJI and EL4 cells by 90%, 70% and 60%, respectively, at 1 µM concentration. The 
selectivity index was greater than 1 which means that its toxicity is more towards malignant cells 




with a CC50 value of approximately 0.45 μM. It also exhibited MDR reverting properties. A 
mechanistic investigation revealed that cell death was caused by apoptosis by activation of 
caspase-3 and caspase-7 and mitochondrial depolarization in Jurkat cells.77,78 
 
In another series of novel curcumin analogues, the N-methyl-4-piperidone moiety and 
incorporation of the hydroxyl groups favoured anticancer activity. Compounds 30a and 30b 
displayed high potency against THP-1 leukemic cells in vitro with IC50 values in the range of 0.69-
0.96 μM. They were also cytotoxic against a number of cell lines namely HepG2, Hela and K562 
cells. Moreover, the phenolic -OH groups contributed to the higher solubility in 20 mM PBS as 
compared to 30a.79 
1.8.3.2 N-Acyl-3,5-bis(benzylidene)-4-piperidones 
These analogs were developed based on the following considerations: (1) An acyl group that serves 
as an auxiliary binding site was introduced onto the piperidyl nitrogen atom of the 1,5-diaryl-3-
oxo-1,4-pentadienyl pharmacophore to investigate whether it increases or retains cytotoxicity. (2) 
It is challenging for 3,5-bis(benzylidene)-piperidones to pass through the cell membrane as they 
tend to ionize in the body under various physiological conditions. Addition of a N-acyl group onto 
the piperidyl nitrogen atom will prevent possible ionization of the piperidyl nitrogen and hence the 
permeability in neoplasms may increase.  
Two important characteristics of these compounds are that these groups can form van der Waals, 
hydrogen and ionic bonds with cellular moieties. These analogs can also act as prodrugs 





Figure 1.10 : N-Acylation of 3,5-bis(benzylidene)-4-piperidones. 
 
These compounds were prepared with the aim to increase cytotoxic potencies and display 
selectivity towards malignant cells and interact at a N-acyl binding site. The N-acryloyl derivatives 
displayed greater antineoplastic activity against four different cell lines namely murine P338, 
L1210 leukemic cells, human Molt 4/C8 and CEM neoplasms than the analogues in which a 
hydrogen atom was present on the piperidyl nitrogen atom. The average IC50 values of 31a-e were 
0.28 μM (P388), 4.71 μM (L1210), 0.96 μM (Molt 4/C8) and 1.13 μM (CEM), respectively. 
Overall, there was 25-fold increase in cytotoxicity for N-acryloyl analogues when their average 
IC50 values were compared with the corresponding parent compounds in these four cell lines. The 




3-fold as compared to the corresponding 3,5-bis(benzylidene)-4-piperidone 25a (IC50 = 2.5 μM) 
against the L1210 leukemic cells in vitro. Thus the addition of third alkylating site led to an 
increase in potency of the cytotoxins.80  
Moreover, NCI screening of 31a against a series of 56 different cancer cell lines revealed it had 
an average IC50 value of 1.45 μM. This means that 31a is approximately 18-fold more potent than 
a reference alkylating cytotoxic drug melphalan (IC50 = 26.30 μM).
80 Although substitution of the 
carboxyl moeity (R=COCH=CHCOOH) increased potency 700 times compared to BCNU (IC50 = 
134 pM) in P338 cells, it was less active than 25a and it is believed that the polar carboxyl group 
may have hindered its permeation into the cells. However, hepatic glutathione levels were reduced 
by 29% when a dose of 0.87 mmol/kg was administered in mice.63 Further, 31e inhibits DNA, 
RNA, and protein synthesis in murine L1210 cells whereas 31c induces apoptosis in human Jurkat 
leukemic cells. Structure-activity relationships shows that electronic parameters influence 
cytotoxicity. The contributing features towards enhancement of potency can be the incorporation 
of strong electron-withdrawing groups in the arylidene benzene ring, addition of substituents of 
varying sizes in the ortho position of the aryl rings to increase the torsion θ values and insertion of 
groups having lower redox potentials.64 Another important characteristic of 31a-e is that they show 
higher selectivity towards neoplasms than normal cells. N-Acryloyl-3,5-bis(benzylidene)-4-
piperidone 31a is considered a lead compound. 
 
All the compounds in series 32 were potent inhibitors of L1210 leukemic cells. Compound 32b 
displayed 1.6-fold greater potency than 31 while the dimethylamino and pyrrolidino analogues 
showed similar potency as 31. Substitution of electron-withdrawing groups to the arylidene aryl 
ring 33 further increased their cytotoxicity 4-fold and 13-fold compared to the corresponding 




compounds 32 were designed as prodrugs which are believed to liberate 31. Solubility studies 
showed that all the compounds were poorly soluble in PBS except 32a and 32b which were 
dissolved in a mixture of PBS-d: DMSO-d6. 
1 H NMR studies after incubation at 37°C for 48 h 
revealed that compound 32 liberates 31 which was unstable in the solvents used in the experiments. 
It was also noted that the potency of compound 32 was greater before its decomposition. Thus 
decomposition of N-acyl group can be avoided if methyl groups can be introduced adjacent to the 
N-acyl group.80 
Another novel series of N-acyl analogues of 3,5-bis(arylidene)-4-piperidone 34 and 35 were 
developed as potential cytotoxins which supports the hypothesis that the N-acyl moiety will act as 
a third alkylating site capable of forming van der Waals, hydrogen and ionic bonds with the 
receptor. The 1-[4-(2-alkylaminoethoxy)phenylcarbonyl]-3,5-bis(arylidene)-4-piperidone 
hydrochlorides  34 are cytotoxic against a panel of human colon cancer cells displaying IC50 values 
in the submicromolar to nanomolar range and the  average IC50 values are lower than a reference 
drug 5-FU. 
 
The structure-activity relationships were developed by incorporating different substituents with 
varying Hammett σ and Hansch π values in the arylidene aryl rings and incorporating a number of 
various amines with different sizes and basicity in the N-acyl side chain. The potencies of the 
compounds in series 34 are either increased, equipotent or decreased in 48%, 35% and 17%, 
respectively, to the corresponding analogues of the parent compound 25. Overall, higher cytotoxic 




38 times higher potencies than the reference drug melphalan. Compound 34b was a lead compound 
with IC50 = <5 nM against colon cancer HCC-2998 cells.
81 The compounds in series 34 
demonstrated greater toxicity to the neoplastic HL-60, HSC-2 and HSC-4 tumor cells than non-
malignant HGF, HPC and HPLF normal cells. Compound 34b possessing morpholine as the 
terminal base displayed higher selectivity towards neoplasms with a SI value of 69 which is 
noteworthy. This observation suggests that the N-acyl group contributes to the preferential 
cytotoxicity to the malignant cells compared to the normal cells. This compound induces apoptosis 
by activation of caspase-3 and internucleosomal DNA fragmentation in HL-60 cells. Additionally, 
it caused autophagy in HSC-2 cells.82 Moreover, these compounds are well-tolerated in mice up 
to a 300 mg/kg dose without noteable toxicities.67 Compounds 35a and 35b showed similar 
potencies as the parent compound 25a whereas the presence of a dimethylaminoethoxy group in 
35c displayed greater potency (IC50 = 0.58 μM) than 25a (IC50 = 1.67 μM) in Molt 4/C8 cells 
supporting the hypothesis that the 4-(2-aminoethoxy) fragment serves as auxiliary binders 
interacting with the cellular constituents. Thus, the N-[4-(2-aminoethoxy)phenylcarbonyl] side 
chain is believed to interact at auxiliary binding sites and contributes to the increased potencies. 
 
A series of novel compounds 36 were prepared from our lab with mercaptosulfonic acid which are 
potential cytotoxins based on the hypothesis that mercaptosulfonic acid will be released in vivo by 
undergoing dethiolation under suitable physiological conditions. The sodium salt of 
mercaptosulphonic acid (mesna) acts as a chemoprotectant when co-administered with 
antineoplastic agents and thus it was hypothesized that incorporation of this group will demonstrate 
selective toxicity towards neoplasms. However, compound 36a showed poor potency towards 
HSC-2 and HSC-4 squamous carcinoma cells, murine L1210, HL-60 and Molt/C8 and CEM T-
lymphocytes as well as no selectivity towards cancer cells and it is believed that the incorporation 




Stability studies shows that derivatives of 36a at 37°C for 24 h do not release 1-acryloyl-3,5-
bis(benzylidene)-4-piperidones and mesna. To overcome this problem, the sulfonic acid group was 
replaced by a mercapto group 36b which increased the logP value to 3.23. In general, an analogue 
36b possessing a nitro group in the benzylidene ring displayed more potency than other 
substituents and greater potency than 36a.65 This thiol 36b is equipotent to melphalan against Molt 
4/C8 and CEM cell lines.83  
A related series of dienones such as 3,5-bis(benzylidene)-1-[3-(2-hydroxyethylthio)-propanoyl]-
piperidin-4-ones 37, displayed high potencies against a wide range of cancer cell lines especially 
colon cancers and leukemias with IC50 values in the submicromolar range and are significantly 
more potent than the reference drug melphalan. The compound possessing nitro substituents in 
series 37 was found to be the most potent with IC50 values in range of 0.02-0.28 μM against a panel 
of cancer cells. It displayed 96 times greater potency than melphalan. Statistical analysis showed 
a negative correlation between the σ values of the aryl substituents and CC50 values in HL-60, 
HSC-3 and HSC-4 bioassays suggesting that by increasing the electron-withdrawing properties of 
the aryl substituents will result in a higher positive charge on the olefinic carbon atoms and thereby 
increase potency. Moreover a positive correlation was observed between the σ values of aryl 
substituents and SI values of compounds in series 37 in the HL-60, HSC-3 and HSC-4 bioassays 
suggesting that with increases in the electron-withdrawing properties of the aryl substituents, 
greater toxicity is observed towards cancer cells than the normal cells. The compounds in series 
37  with nitro and chloro substituents at the para position emerged as potential cytotoxins against 





Another series of dienone derivatives 38 were prepared by replacing the polar hydroxyl group in 
the terminal N-acyl chain of 37 to a methyl ester and by replacing the sulphur atom to an isosteric 
oxygen atom and by incorporating groups having different sizes, electronic parameters and 
hydrogen bond forming capacities. These novel dienones are potent cytotoxins against Molt4/C8 
and L1210 leukemic cells and displayed higher toxicity than melphalan. The results in this study 
supports the hypothesis that addition of the 3-(2-methoxyethylthio)-propionyl group in 38a, shows 
higher potency or are equipotent than their corresponding parent analogues 25 and 37 when 
comparisons were made. This suggests that these compounds undergo interactions at secondary 
binding sites. Compound 38a having a 4-nitro substituent (CC50 = 0.36 μM in HSC cell lines) was 
35 times more potent than the reference drug melphalan. Furthermore addition of an isosteric 
oxygen atom in 38b remarkably lowered the potency. Compounds in series 38c-d with a 4-fluoro 
substituent at the R1 position were found to be more cytotoxic than the corresponding parent 
compound 25 and twice as potent as the 4-fluoro analogues in 38a. Overall, replacing sulphur 
atoms with large sized atoms results in higher electron-attracting properties thereby increasing or 
retaining potency. Compounds with terminal polar -OH groups resulted in lower IC50 values than 
38a possessing a methoxy group. The 3,4-dimethoxy analogues in 38a were potent with an average 
CC50 figure of 0.83 μM and selectivity index of 13. Compounds in 38a with R1 having nitro and 
3,4-dimethoxy groups showed apoptotic death by cleavage of PARP1 in HSC-2 cells. 84 
In general, it can be concluded from the literature studies that N-acyl derivatives of 3,5-
bis(benzylidene)-4-piperidones are a novel class of antineoplastic agents that may possess tumor-
selective properties. Hence, incorporation of a novel N-acyl group into the 3,5-bis(benzylidene)-
4-piperidone moiety may increase or retain cytotoxic potencies.  
1.8.3.3 Other 3,5-bis(benzylidene)-piperidone derivatives 
Various groups have been placed on the piperidyl nitrogen atom to observe the potential interaction 
of auxiliary binders with the cellular constituents. 
Another series of dienone derivatives, the N-diethylphosphono-4-piperidones 39 and 3,5-
bis(benzylidene)-4-oxo-1-phosphonopiperidines 40 have been developed which inhibits the 
growth of human Molt4/C8 and CEM T-lymphocytes and murine L1210 leukemic cells.  Overall, 
compounds 39a-c and 40c displayed 58-, 35- 93- and 15-fold greater potency than melphalan 




cytotoxins meeting the criteria of PL10 status (that is compounds are identified as promising lead 
molecules if they have CC50 values of 10 μM or less and SI of 10 or more). 
The average CC50 figures (SI values in parentheses) of 39b and 40b were 1.20 μM (46) and 3.35 
μM (25) respectively. Moreover, all the compounds showed selectivity towards neoplastic cell 
lines (HL-60, HSC-2, HSC-3 and HSC-4) compared to human normal cells (HGF gingival 
fibroblasts, HPC pulp cells and HPLF periodontal ligament fibroblasts).86 
 
Compound 40d was identified as lead molecule with IC50 value of 34 nM against both Molt 4/C8 
and CEM T-lymphocytes. It displayed 90-fold and 76-fold more potency than melphalan in the 
Molt4/C8 and CEM tests respectively. It was concluded from QSAR studies that substitution of 
large electron-withdrawing groups with low hydrophobicity in the benzylidene ring could be 
fruitful in the development of potent cytotoxins. The positive correlation between IC50 values and 
ClogP suggests that hydrophilic groups like the phosphonic acids 40 have lower potency than the 
ester moiety 39 in L1210 cells and therefore increasing Hansch π values in the aryl substituents 
may be fruitful. In general, series 40 has greater growth-inhibiting properties than series 39. 
Compounds 39a and 39b were potent towards RPMI leukemic cells with IC50 values of <10 nM 
and 32 nM, respectively, which is noteworthy. A further investigation revealed that 40d induced 
apoptosis in HT-29 colon cancer cells at a concentration of 5 μM with a 29-fold increase in the 
sub-G1 phase and inhibited cellular respiration. Moreover compounds 39 and 40 possess MDR 





A series of novel fluorescent antitumor agents were synthesized with the aim that these agents will 
not only be cytotoxins but will also possess fluorescent properties which can be useful to trace 
targets in the cell. These compounds were potent inhibitors of the growth of five malignant cell 
lines namely, SW1990 and MIA PaCa-2 (human pancreatic carcinoma), PG-BE1 and NCI-H460 
(human lung carcinoma) and SK-BR-3 (human breast cancer). Compounds 41a, 41d and 41e were 
the most potent with average IC50 values of 0.98 μM, 0.67 μM and 0.36 μM, respectively, in these 
cell lines. It is possible that the electron-withdrawing trifluoromethyl group and the interaction of 
the N-substituent with cellular constituents contributed to the higher potencies than the parent 
compounds. Moreover, X-ray crystallography suggests that the short distances between the N-
substituent (4-nitrophenylsulfonyl groups) and 3,5-bis(benzylidene)-4-piperidones results in an 
interconjugated system and thereby contributes towards the fluorescent properties. The fluorescent 
intensities of 41a-e with trifluoromethyl substituents were not as strong as compared to compounds 
possessing electron-donating groups like dimethylamino. In addition, there exists an inverse 
relationship between cytotoxicity and fluorescent properties. The N-aroyl derivatives 41a-e are 





The following study highlighted the incorporation of small N-substituents in 3,5-bis(benzylidene)-
4-piperidones. The diesters 42a-b had shown poor cytotoxicity against four human adherent 
carcinoma cell lines Hela, A2780, MCF7 and A431 compared to the parent analogues 25. On the 
other hand, the dienones 43 were potent cytotoxins against these four malignant cell lines. It can 
be noted that compounds 43 are potent antineoplastic agents as they possess oxygen atoms which 
can interact with the auxiliary binding sites by forming hydrogen bonds. Compound 43a with R1 
having a chloro substituent (average IC50 = 0.84 μM) was more potent than unsubstituted analogue 
(R1= H, average IC50 = 2.61 μM) and displayed 28 times greater potency than cisplatin which is a 
drug used in chemotherapy. Moreover, the long chain monoesters 43b had a 2.4-fold increased 
cytotoxicity than 43c. The positive correlation of the atomic charges of the olefinic carbon atoms 
in the aryl ring and cytotoxicity suggests that chlorobenzylidene derivatives are more potent than 
corresponding benzylidene ones.88 
1.9 Importance of N1-acylhydrazide derivatives  
Hydrazide and hydrazone functional groups which are present in many biomolecules contributing 
towards various pharmacological activities such as anti-inflammatory, antiviral, antibacterial, 
antitubercular, antifungal, antiprotozoal and anticancer activities. The azomethine group in 
hydrazones (NH-N-CH=) bridged with the carbonyl group mainly contributes towards its 
biological activity as well as the synthesis of various heterocyclic scaffolds like 1,3,4-
oxadiazolines, azetidin-2-ones, coumarins, 1,3-benzothiazin-4-ones and 1,3-thiazolidin-4-





Dimmock et al synthesized various acetylhydrazone and semicarbazone derivatives 44 which 
showed promising anticonvulsant activity. These compounds were believed to interact with 
cellular peptides by forming hydrogen bonds as shown in the figure, as well as with an aryl binding 
site. If the terminal group is methyl then it facilitates van der Waals formation and with amino and 
aminocarbonyl groups, there is formation of hydrogen bonding with the binding site.91 
 
A series of nitrogen containing heterocyclic 4H-1,3,4-oxadiazin-5(6H)-ones derivatives were 
synthesized by cyclization reaction of N-aroylhydrazines with chloroacetyl chloride. Compound 
46a having a trimethoxy moiety was the most potent growth inhibitor of human lung A549 cancer 
cells and human prostate PC-3 cell lines with IC50 values of 9.91 µM and 14.42 µM, respectively. 
In another assay, compound 45a displayed monoamine oxidase (MAO) inhibitory activity with an 
IC50 value of 0.24 mmol/L.
92 
 
In a recent study, the hydrazone derivative 47 emerged as a lead cytotoxin towards esophageal 
cancer cells EC9706 and EC109 with IC50 values of 1.09 µM and 2.79 µM, respectively. This 
compound was synthesized by the conjugation of a hydrazone and sulfonamide moiety in an 
approach to study potential synergistic effects of these scaffolds. Structure-activity relationship 
revealed that the substitution on the phenyl ring has significant effects on cytotoxicity. The 
hydroxyl group at the ortho position of the phenyl ring improved the cytotoxic potency. The 
replacement of the phenyl ring with furan or thiophene groups led to compounds with IC50 values 
in excess of 100 µM; however in the case of the pyridine moiety, the cytotoxicity was increased 




the G0/G1 phase, collapses the mitochondrial membrane potential, increases ROS levels, 
upregulates the pro-apoptopic protein Bax and p53 as well as downregulates anti-apoptopic Bcl-2 
by activating caspase-9 in EC9706 and EC109 cells. Furthermore it was well tolerated in mice 
with a dose of 2 g/kg for 2 weeks and no signs of toxicities were noted.93 
 
The triazole derivatives 48 and the acyl hydrazide 49 inhibit two main targets namely cathepsin B 
and cathepsin H in cancer which belong to the cysteine protease family. These cysteine proteases 
play important roles in the regulation of cellular proteins and increased enzyme levels are 
associated with tumor progression. Compounds having amino, nitro and chloro groups at the 3 and 
5 positions of the 1,2,4 triazole ring and 4-methoxy benzohydrazide 49 inhibited the proteolytic 
activities in liver homogenate. The acyl hydrazide 49 inhibited cathepsin B competitively and 
cathepsin H non-competitively whereas the triazoles 48 inhibited cathepsin H in a non-competitive 
fashion.94 
 
Novel bis(indolyl)-hydrazide 50 derivatives were synthesized wherein an indole ring is linked to 
an acyl hydrazone (-CO-NH-N=CH-) pharmacophore. These compounds are potent cytotoxic 
agents and display higher selectivity against human lung A549 cancer cells (50a: IC50 = 2 µM, 
50b: IC50 = 6 µM,) than normal human lung W138 fibroblasts (50a: IC50 = 48.5 µM) and peripheral 
blood mononuclear PBMC cells (50a: IC50 = 62 µM). SAR studies revealed that compound 50a is 
the most potent cytotoxin. The mode of action studies involved cell-cycle arrest at the G2/M phase, 
mitochondrial membrane depolarization and apoptosis by inhibiting microtubules (62%) with an 




were noticed with a decrease in the level of Bcl-2 expression in A549 cells. Additionally, 
compound 50a exhibited remarkable fluorescent properties on binding with tubulin.95 
 
Compounds 51a (furan substituent) and 51b (thiophene substituent) were cytotoxic towards MCF-
7 adenocarcinoma cells with IC50 values of 0.7 µM and 0.18 µM, respectively, as compared to 
doxorubicin as a reference drug with an IC50 value of 2.1 µM. Compound 51b exhibited a 4-fold 
greater cytotoxic potency than 51a.  Moreover, it showed less toxicity towards normal human 
fibroblasts cells. Compound 51b induced apoptosis by up-regulating Bax levels, downregulating 
Bcl-2 levels and activating caspase 3. It also inhibited the growth of a mammary tumor at doses of 
10 mg/kg/day in mice.96 
Another dehydroabietic acid-based acylhydrazone derivative 52 was synthesized by a 
condensation reaction. N′-(3,5-difluorobenzylidene)-2-(dehydroabietyloxy)acetohydrazide 52 is a 
potent cytotoxin against cervical HeLa cancer cells with an IC50 value of 2.21 µM which is a 
similar potency as cisplatin (IC50 = 1.94 µM). Moreover, it displayed cytotoxicity towards liver 
BEL-7402 cancer cells with an IC50 value of 14.46 µM which is the same potency as cisplatin 
(IC50 = 12.68 µM). SAR studies revealed that a methyl group at the para position, bromo at ortho 
position and bifluoro groups at the ortho, para and meta positions in the aryl ring of the 
acylhydrazone moiety increases cytotoxicity towards HeLa cells.97 
Tolmetin, 2-[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]-acetic acid belongs to the non-
steroidal anti-inflammatory drug (NSAIDs) class known to inhibit prostaglandin synthesis but it 
also prevents cell proliferation in colon neoplasms. Tolmetin based hydrazide derivative 53 
displayed antineoplastic activity against colon cancer HT-29 cells with an IC50 value of 76 µM. 
The mode of action studies revealed that Tolmetin and compound 53 significantly increases 
caspase-3, -8 and -9 concentrations as well as annexin V levels with a dose of 75-100 µM in colon 





In addition, it also decreased the mitochondrial membrane potential in HT-29 cells at a 
concentration of 75-150 µM. Moreover, it is believed that cyclooxygenase-2 (COX-2) has elevated 
levels in colon adenomas. Computational studies predicted that both tolmetin and compound 53 
bind selectively to the COX-1 active site rather than COX-2 enzyme. Moreover, compound 53 has 
higher binding affinity than tolmetin for COX-1. Thus compound 53 was considered to be a novel 
hydrazide derivative with antineoplastic activity.98 
 
 
The homologous series of methane (561a), ethane (54b), propane (54c) and butane (54d) sulfonic 
hydrazide derivatives were synthesized by a nucleophilic substitution reaction of alkyl sulfonyl 
chloride with hydrazine hydrate. An in vitro cytotoxicity study showed that the compound with 
the lowest IC50 (15.41 µM) is 54d as compared to docetaxel (IC50 = 7.24 µM) towards MCF-7 
breast adenocarcinoma cells revealing that there is enhancement in cytotoxicity with an increase 
in the number of methylene groups. Furthermore the butane sulfonic acid hydrazide 54d has shown 
remarkable antibacterial activity against Gram positive and negative bacterial strains as well as it 







In another study a 2-(4-alkoxyphenyl)-N’-(phthalazine-1-yl)cyclopropanecarbohydrazide 55 and 
a 3-(2-(4-alkoxyphenyl) cyclopropyl)-[1,2,4]triazolo[3,4-α]phthalazine 56 exerted anticancer 
activity via cytostatic effects rather than a cytocidal effect. SAR studies revealed that 1-
phthalazines may be responsible for the inhibition of DNA synthesis in cancer cells by acting as 
DNA-intercalators. Moreover, it is believed that the phenyl cyclopropyl fragment contributes to 
potent cytotoxicity. Compounds 55 with geranyl and 56 with isopentyl side chains attached to 4-
hydroxylphenyl frame were active against U373 glioblastoma (GBM, IC50 values 9 µM and 4 µM, 
respectively) and OE21 esophageal cancer cells (IC50 values 9 µM and 8 µM, respectively). These 
compounds impeded U373 tumor growth by decreasing cell proliferation rather than killing U373 
tumor cells. Compound 55 showed mitosis dependent cytotoxic effects by prolonging the mitosis 
duration thereby reducing mitosis numbers in U373 GEM cells at 10 µM whereas compound 56 
exerted independent cytotoxic effects by decreasing mitosis duration but there were no changes in 
mitosis numbers in vitro. 100 
 
Novel quinoline based hydrazide-hydrazones analogues were synthesized based on the fact that 
conjugation of the quinoline moiety onto the hydrazide-hydrazones [(-C=O)NHN=CH] fragment 




plays a crucial role in the regulation of G0  to S phase transition in cell-cycle via regulating cyclin-
dependent kinases. All the compounds in series 57 inhibit the growth of SH-SY5Y and Kelly 
neuroblastoma as well as MDA-MB-231 and MCF-7 breast adenocarcinoma cells. However it was 
observed that these acyl hydrazone compounds display greater cytotoxicity and selectivity towards 
neuroblastoma cells rather than breast cancer cells. It was noted that 57c possessing two methoxy 
groups was the most active against SH-SY5Y (IC50 = 2.9 µM), Kelly (IC50 = 1.3 µM), MCF-7 
(IC50 = 14.1 µM), and MDA-MB-231 (IC50 = 18.8 µM), malignant cells respectively. 
Moreover, compound 57b having an ether linkage exhibited higher cytotoxic potency than 
compound 57a possessing a sulfane linkage. Further SAR revealed that the hydrazides having 
short chains such as in compound 57a (n = 1, X = S) reduced the cell viability up to 37% more 
than compound 57d (n=1, X = S) in Kelly cells. Additionally, 57b (n = 1, X = O) decreased cell 
viability up to 53% more than the compound bearing a long chain 57e (n = 4, X = O) in SH-SY5Y 
cells. It was also found that the size of the heterocyclic moiety plays an important role in 
cytotoxicity. For example, replacement of the quinoline moiety with indole and phenyl derivatives 
lowered cytotoxicity whereas the naphthalene group showed similar cytotoxicity across cell lines 
as 57. Mode of action studies revealed that 57c increased proportions of the G0/G1 phase as well 
as decreased the number of cells in the S and G2/M phases at 10 µM concentration and induces 
cell cycle arrest by upregulating p27kip1 in SH-SY5Y neuroblastoma cells. Thus, these hydrazide 
compounds are potential anticancer agents against neuroblastoma with less toxicity towards 
normal lung fibroblasts cells.101 
1.10 Mitochondria: an important target for cell death  
Mitochondria, the power house of the cell, is an important target for anticancer agents as it plays 
a vital role in the regulation of cellular processes such as ATP production, biosynthesis, 
metabolism and apoptosis. The disruption of mitochondria either by causing a loss of ATP 
production, the collapse of mitochondrial membrane potential or decreased oxygen consumption 
leads to cell death. These dysfunctions may be due to enzymatic, transport, structural or regulatory 
failure of mitochondria.102  
Many significant differences have been noted between mitochondria present in cancer and non-
cancerous cells. Under hypoxic conditions, cancer cells inhibit oxidative phosphorylation and 




membrane and also increases VEGF levels which allows the growth of tumors by angiogenesis. 
The overexpression of antioxidant enzymes such as GST in malignant cells helps to scavenge the 
high ROS levels. Inhibition of these enzymes in cancer cells could considerably increase ROS 
levels.103 Moreover cancer cells have a more hyperpolarized mitochondrial membrane potential 
(Δψm ~ -220 mV) than the healthy cells (Δψm ~ -140 mV).  
Mitochondrial membrane potential results from the transfer of protons across the inner 
mitochondrial membrane by the respiratory pumps during aerobic respiration. This build-up of 
proton force generates an electrochemical gradient across the hyperpolarized membrane to produce 
energy in the form of ATP. CCCP and 2,4-dinitrophenol are lipophilic uncouplers which can cross 
the membrane and accumulate inside the polarized mitochondrial matrix. These uncouplers, when 
targeted to cancer cells,  depolarize the potential by opening the permeability transition pore and 
release pro-apoptotic agents such as cytochrome c into the cytoplasm and consequently induces 
apoptosis at higher doses.104 The regulation of MMP in healthy cells is vital because high Δψm 
during the electron transport process results in an increase in ROS levels. On the contrary, if Δψm 
drops then there is less energy production and low ROS levels may dissipate cell homeostasis.105 
Therefore, the dysregulation of Δψm results in a loss of cell viability.  
Reactive oxygen species generated in the electron transport chain across the membrane results in 
the oxidation of endogenous molecules initiating a caspase activation pathway.106 Apoptosis, 
which may be defined as programmed cell death, depends on the activation of caspases wherein 
oxidative stress, Ca+2 overload, DNA damage, high ROS levels can directly lead to the initiation 
of apoptosis. Thus targeting mitochondria in cancer cells can be one of the key strategies for 
apoptosis which can achieved with different pathways such as damaging mitochondrial DNA, 
targeting metabolic pathways as well as effects on the mitochondrial membrane. Results from our 
lab have shown the effect of unsaturated carbonyl compounds on mitochondria.107,108 Hence, 
mitochondrial membrane potential and evaluation of ROS levels have been undertaken to 






Chemotherapy is a well-known treatment option for treating cancer however its debilitating effects 
such as nausea, vomiting, hair loss, susceptibility to infections and other health problems needs to 
be overcomed. Thus advances are being made by researchers to design and develop antineoplastic 
agents which can kill the tumors without having detrimental effects on normal healthy cells. 
Moreover tumors develop intrinsic or extrinsic resistance mechanisms to overcome the effects of 
the chemotherapeutic agent. Curcumin isolated from turmeric has shown proven efficacy treating 
cancer with a limited therapeutic profile. Hence, the need to develop synthetic analogs of curcumin 










CHAPTER 2 : HYPOTHESES AND OBJECTIVES 
2.1 Hypotheses 
1.  The attachment of a suitable group on the nitrogen atom of antineoplastic 3,5-bis(benzylidene)-
4-piperidones 63 will lead to analogs with increased cytotoxic potencies.57, 64 
 
 
2. Representative N1-aroyl-N2-acryloylhydrazines 60 will sensitize human HCT 116 colon cancer 
cells to 3,5-bis(benzylidene)-4-piperidones 63.  
3. N1-aroyl-N2-acylhydrazines in series 62 will be less cytotoxic than N1-aroyl-N2-




4. An adduct 64 between a representative compound in series 60 and a 3,5-bis(benzylidene)-4-
piperidone in series 63 will have greater potency than the corresponding compounds in series 
60 and 63. 
2.2 Objectives 
1. To synthesize a series of cytotoxic N1-aroyl-N2-acryloylhydrazines 60, N1-aroyl-N2-3-
arylcarboxamidoaminopropionylhydrazines 61, N1-aroyl-N2-acylhydrazines 62 and 3,5-
bis(benzylidene)-1-[3-(arylcarboxamidoamino)-3-oxo-1-propyl]-4-piperidone 64. 
2. To establish the activity of these agents against HCT 116, MCF-7 and MDA-MB-231 cancer 
cell lines. Selected compounds will be evaluated against non-malignant human CRL1790 colon 
cells. 
3. To evaluate whether one or more representative compounds in series 60 sensitize HCT 116 cells 
to 3,5-bis(benzylidene)-4-piperidones 63. 
4. To investigate some of the mechanisms of action of representative compounds such as their 
effects on mitochondrial membrane potential, generation of reactive oxygen species (ROS) 














CHAPTER 3 : SYNTHESIS 
3.1 Materials and Methods 
All the chemicals and solvents used are of analytical grade and are used without further 
purification. Melting points (m.p.) were measured on a Gallenkamp instrument (MF370) and are 
uncorrected. Thin layer chromatography (TLC) was used to monitor the chemical reactions for 
which silica gel 60, F254 precoated plates were used and visualized under UV light or an iodine 
chamber. 1H and 13C Nuclear Magnetic Resonance (NMR) were recorded at 500 MHz and 125 
MHz, respectively, using a Brüker Avance spectrometer equipped with a 5mm BBO probe. NMR 
spectra were obtained by dissolving the samples either in deuterodimethyl sulphoxide (DMSO-d6) 
or deuterochloroform (CDCl3) relative to tetramethylsilane (TMS) or solvent. The NMR spectra 
were determined in terms of the chemical shifts which are expressed in parts per million (ppm). 
Different designations were used to indicate the multiplicity namely, s (singlet), d (doublet), dd 
(doublet of doublet), t (triplet), q (quartet), m (multiplet) and br (broad). Mass spectra were 
obtained using QSTAR XL LC/MS/MS quadrupole / time of flight mass spectrometer with an ESI 
source. 
3.2 General scheme for the synthesis of N1-aroyl-N2-acryloylhydrazine derivatives 60a-m 
The general methodology for the synthesis of 60a-m is presented in scheme 3-1. 
 
Scheme 3.1 : General scheme for the synthesis of N1-aroyl-N2-acryloylhydrazines 60a-m. 
The reaction conditions are as follows: a: ethanol/H2SO4, reflux temperature, 6-8 h; b: hydrazine 
hydrate/ethanol, reflux temperature, 8-12 h; c: acryloyl chloride/CHCl3, NaHCO3 /water, 0°C, 1 h. 
a: R1 = R2 = R3 = R4 = R5 = H; b: R1 = R2 = R4 = R5 = H, R3 = F; c: R1 = R2 = R4 = R5 = H, R3 = Br; 
d: R1 = R2 = R4 = R5 = H, R3 = Cl; e: R1 = Cl, R2 = R3 = R4 = R5 = H; f: R1 = R3 = R4 = R5 = H, R2 = 
Cl; g: R1 = R4 = R5 = H, R2 = R3 = Cl; h: R1 = R4 = Cl, R2 = R3 = R5  = H; i: R1 = R3 = R4 = R5 = H, 
R2 = CH3; j: R1 = CH3, R2 = R3 = R4 = R5 = H; k: R1 = R2 = R4  = R5  = H, R3 = CH3; l: R1 = R2 = R4  




3.2.1 Synthesis of the esters 58a-m 
Substituted or unsubstituted benzoic acids (0.0082 moles, 1 g), ethanol (0.085 moles, 5 ml) and 
sulphuric acid (0.0094 moles, 0.5 ml) were heated under reflux for 6-8 h.109 Ethyl acetate and 
hexane (1:1) were used as the TLC solvent to monitor the reaction. In the case of 58g and 58m, a 
precipitate was formed from the solution at room temperature. In the case of the other compounds, 
the solvent was removed and the residues were collected. For purification, these residues were 
added to ethyl acetate (20 ml) and washed twice with saturated sodium bicarbonate solution (20 
ml). The aqueous solution was discarded and the ethyl acetate solution containing the esters was 
rinsed with brine solution (20 ml), dried over sodium sulphate and further solvent evaporation in 
vacuo yielded the esters. All the esters prepared are liquid in nature except 58g and 58m which are 
solids. For all the esters synthesized, 1H NMR spectra obtained are consistent with their structure. 
Data for three representative compounds 58a, 58g and 58m are as follows: 
Ethyl benzoate (58a): Colorless liquid; Yield = 83%; 1H NMR (CDCl3): δ 8.08 (dd, J = 8.32 Hz, 
1.31 Hz, 2H, Ar-H), 7.54 (m, 1H, Ar-H), 7.45 (m, 2H, Ar-H), 4.40 (q, J = 14.25 Hz, 7.12 Hz, 2H, 
CH2), 1.39 (t, J = 7.12 Hz, J = 14.23 Hz, 3H, CH3). 
Ethyl 3,4-dichlorobenzoate (58g): Colorless crystals; Yield = 76%; m.p. 37°C (lit. m.p. 35-37 
°C);110 1 NMR (CDCl3): δ 8.12 (d, J = 1.92 Hz, 1H, Ar-H), 7.87 (dd, J = 8.36 Hz, 1.95 Hz, 1H, Ar-
H), 7.52 (d, J = 8.38 Hz, 1H, Ar-H), 4.40 (q, J = 14.25 Hz, 7.16 Hz, 2H, CH2), 1.40 (t, J = 7.17 Hz, 
J = 14.33 Hz, 3H, CH3). 
Ethyl 3,4-dimethoxybenzoate (58m): Colorless crystals; Yield = 71%;  m.p. 42-44 °C (lit. m.p. 
43-44°C);111 1H NMR (CDCl3): δ 7.69 (dd, J = 8.42 Hz, 1.75 Hz, 1H, Ar-H), 7.55 (d, J = 1.63 Hz, 
1H, Ar-H), 6.88 (d, J = 8.46 Hz, 1H, Ar-H),4.36 (q, J = 14.28 Hz, 7.19 Hz, 2H, CH2,), 3.94 (s, 6H, 









Table 3.1 : Physical and chemical properties of 58a-m 







58a H Colorless liquid -- -- 83 
58b 4-F Slightly yellow liquid -- -- 76 
58c 4-Br Slightly yellow liquid -- -- 52 
58d 4-Cl Colorless liquid -- -- 78 
58e 2-Cl Slightly yellow liquid -- -- 78 
58f 3-Cl Slightly yellow liquid -- -- 85 
58g 3,4-Cl2 Colorless solid crystals 37-39
 35-37110 76 
58h 2,5-Cl2 Slightly red brown liquid -- -- 75 
58i 3-CH3 Yellow liquid -- -- 73 
58j 2-CH3 Yellow liquid -- -- 81 
58k 4-CH3 Colorless liquid -- -- 89 
58l 4-OCH3 Slightly yellow liquid -- -- 86 
58m 3,4-(OCH3)2 Colorless solid crystals 42-44
 43-44111 71 
3.2.2 Synthesis of the hydrazides 59a-m 
Solutions of hydrazine hydrate (33.3 mmoles, 1.67 ml, 50-60% w/v aqueous) and ethyl benzoate 
(6.66 mmoles, 1 g) in ethanol (85.7 mmoles, 5 ml) were heated under reflux for 8-12 h.112 The 
reaction was monitored by TLC using chloroform and methanol (9.5:0.5) as the solvent system. 
After completion of the reaction, the solvent was removed in vacuo and recrystallized from 95% 
ethanol. For all the hydrazides synthesized, 1H NMR spectra obtained are consistent with their 
proposed structure. Data for three representative compounds 59a, 59g and 59m are as follows: 
Benzohydrazide (59a): Colourless crystals; Yield = 75%; m.p.110°C (lit. m.p. 112°C);109 1H 
NMR (DMSO-d6): δ 9.76 (s, 1H, CONH), 7.81 (d, J = 7.87 Hz, 2H, Ar-H), 7.51 (t, J = 6.9 Hz, J = 
13.78 Hz, 1H, Ar-H), 7.44 (t, J = 7.6 Hz, J = 15.17 Hz, 2H, Ar-H), 4.48 (s, 2H, NH2). 
3,4-Dicholorbenzohydrazide (59g): Colourless crystals; Yield = 93%; m.p. 167-170°C (lit. m.p. 
154-166°C);110 1H NMR (DMSO-d6): δ 9.96 (s, 1H, CONH), 8.04 (d, J = 1.94, 1H, Ar-H), 7.80 




3,4-Dimethoxybenzohydrazide (59m): Colourless crystals; Yield = 91%; m.p. 148-150°C (lit. 
m.p. 151-152°C);113 1H NMR (DMSO-d6): δ 9.63 (s, 1H, CONH), 7.43 (td, 2H, Ar-H), 7.00 (d, J 
= 8.38 Hz, 1H, Ar-H), 4.47 (s, 2H, Ar-H), 3.79 (d, J = 1.85 Hz, 6H, 2xOCH3).  
Table 3.2 : Physical and chemical properties of 59a-m 







59a H Colorless crystals 110-112 112109 95 
59b 4-F Slightly yellow crystals 160-162 162109 69 
59c 4-Br Colorless crystals 166-168 164109 42 
59d 4-Cl Colorless crystals 159-162 163109 66 
59e 2-Cl Colorless crystals 118-121 118-120114 74 
59f 3-Cl Colorless crystals 154-157 158109 93 
59g 3,4-Cl2 Colorless crystals 167-170 154-166
110 73 
59h 2,5-Cl2 Colorless crystals 167-172 168-170
110 35 
59i 3-CH3 Colorless crystals 99-102 97
109 88 
59j 2-CH3 Colorless crystals 118-120 124
109 83 
59k 4-CH3 Yellow crystals 115-118 117
109 90 
59l 4-OCH3 Slightly yellow crystals 134-136 136-140
114 88 
59m 3,4-(OCH3)2 Colorless crystals 148-150 151-152
113 91 
3.2.3 Synthesis of the N1-aroyl-N2-acryloylhydrazine derivatives 60a-m 
The benzohydrazide (7.34 mmoles, 1g) was added to a solution of sodium bicarbonate (8.07 
mmoles, 0.678 g) in water (7.5 ml) and the reaction vessel was placed in an ice bath for 15 min. 
Acryloyl chloride (7.70 mmoles, 0.70 g) in chloroform (7.5 ml) was added dropwise with constant 
stirring to the suspension of the acid hydrazide and stirred at ice-bath temperature for 1 h. The 
reaction was monitored by TLC using a solvent system of chloroform and methanol (9.5:0.5). 
After the reaction was complete, the residues were collected, washed with ice cold water and 
dried.115 For purification, these residues were dissolved in ethyl acetate (20 ml) and washed twice 
with 2N HCl solution (2 x 10 ml). The aqueous solution was discarded and the ethyl acetate 




sodium sulphate. The solvent was removed by evaporation and the solid was recrystallized from 
95% ethanol. 
N1-Acryloylbenzohydrazide 60a: Yield = 86%; m.p. 177-179°C (lit. m.p. 175-178°C);115 1H 
NMR (DMSO-d6): δ 10.34 (d, J = 109.3 Hz, 2H, CONH), 7.88 (m, 2H, Ar-H),7.59 (m, 1H, Ar-H), 
7.50 (m, 2H, Ar-H), 6.35 (q, J = 17.17 Hz, 10.2 Hz, 1H, =CH), 6.23 (dd, J = 17.17 Hz, 2.05 Hz, 
1H, =CH), 5.76 (dd, J = 10.2 Hz, 2.06 Hz, 1H, =CH). 13C NMR (DMSO-d6): 165.40, 163.87, 
132.42, 131.84, 129.36, 128.47, 127.43, 126.93. MS (ESI): m/z 191.08 [M+H] +. 
N1-Acryloyl-4-fluorobenzohydrazide 60b: Yield = 79%; m.p.176-179°C ; 1H NMR (DMSO-d6): 
δ 10.51 (d, J = 1.185 Hz, 1H, CONH), 10.22 (d, J = 1.206 Hz, 1H, CONH), 7.96 (m, 2H, Ar-H), 
7.35 (m, 2H, Ar-H), 6.34 (q, J = 17.11 Hz,10.2 Hz, 1H, =CH),6.23 (dd, J = 17.17 Hz, 2.04 Hz, 1H, 
=CH), 5.76 (dd, J = 10.2 Hz, 2.07 Hz, 1H, =CH). The principal peak [M+H] + was not found in the 
mass spectra however the fragment peak was found. MS (ESI): m/z 105.95 [M+H] +. 
N1-Acryloyl-4-bromobenzohydrazide 60c: Yield = 70%; m.p. 256-259°C; 1H NMR (DMSO-
d6): δ 10.58 (d, J = 1.46 Hz, 1H, CONH), 10.25 (d, J = 1.45 Hz, 1H, CONH), 7.81 (m, 2H, Ar-H), 
7.74 (m, 2H, Ar-H), 6.34 (q, J = 17.3 Hz, 10.16 Hz, 1H, =CH), 6.23 (dd, J = 17.07 Hz, 2.10 Hz, 
1H, =CH), 5.76 (dd, J = 10.21 Hz, 2.06 Hz, 1H, =CH). MS (ESI): m/z 290.97 [M+Na] +, 268.99 
[M+H] +. 
N1-Acryloyl-4-chlorobenzohydrazide 60d: Yield = 73%; m.p. 233-235°C; 1H NMR (DMSO-
d6): δ 10.58 (d, J = 1.45 Hz, 1H, CONH), 10.25 (d, J = 1.49 Hz, 1H, CONH), 7.90 (m, 2H, Ar-H), 
7.6 (m, 2H, Ar-H), 6.34 (q, J = 17.15 Hz, 10.22 Hz, 1H, =CH), 6.23 (dd, J = 17.15 Hz, 2.09 Hz, 
1H, =CH), 5.76 (dd, J = 10.18 Hz, 2.06 Hz, 1H, =CH). MS (ESI): m/z 247.02 [M+Na] +, 225.04 
[M+H] +. 
N1-Acryloyl-2-chlorobenzohydrazide 60e: Yield = 67%; m.p. 165-167°C; 1H NMR (DMSO-d6): 
δ 10.41 (brs, 2H, CONH), 7.52 (m, 3H, Ar-H), 7.44 (m, 1H, Ar-H), 6.33 (q, J = 17.15 Hz, 10.07 
Hz, 1H, =CH), 6.23 (dd, J = 17.13 Hz, 2.13 Hz, 1H, =CH), 5.76 (dd, J =10.09 Hz, 2.13 Hz, 1H, 
=CH). MS (ESI): m/z 262.85 [M+K] +, 247.02 [M+Na] +, 225.04 [M+H] +. 
N1-Acryloyl-3-chlorobenzohydrazide 60f: Yield = 86%; m.p. 155-158°C; 1H NMR (DMSO-d6): 
δ 10.62 (brs, 1H, CONH), 10.28 (s, 1H, CONH),7.91 (t, 1H, Ar-H), 7.84 (m, 1H, Ar-H), 7.67 (m, 




2.06 Hz, 1H, =CH), 5.76 (dd, J = 10.21 Hz, 2.06 Hz, 1H, =CH). MS (ESI): m/z 247.02 [M+Na] +, 
225.04 [M+H] +. 
N1-Acryloyl-3,4-dichlorobenzohydrazide 60g: Yield = 78%; m.p. 172-175°C; 1H NMR 
(DMSO-d6): δ 10.71 (s, 1H, CONH), 10.32 (s, 1H, CONH), 8.11 (d, J = 1.91 Hz, 1H, Ar-H), 7.87 
(dd, J = 8.39 Hz, 2.00 Hz, 1H, Ar-H), 7.81 (d, J = 8.37 Hz, 1H, Ar-H), 6.35 (q, J = 17.18 Hz, 10.24 
Hz, 1H, =CH), 6.23 (dd, J = 17.16 Hz, 2.06 Hz, 1H, =CH), 5.76 (dd, J = 10.16 Hz, 2.04 Hz, 1H, 
=CH). MS (ESI): m/z 280.98 [M+Na] +, 259.00 [M+H] +. 
N1-Acryloyl-2,5-dichlorobenzohydrazide 60h: Yield = 69%; m.p. 207-210°C; 1H NMR 
(DMSO-d6): δ 10.60 (d, J = 1.93 Hz, 1H, CONH), 10.45 (d, J = 1.93 Hz, 1H, CONH), 7.60 (m, 
2H, Ar-H), 7.53 (m, 1H, Ar-H), 6.33 (q, J = 17.11 Hz, 10.09 Hz, 1H, =CH), 6.24 (dd, J = 17.14 
Hz, 2.14 Hz, 1H, =CH), 5.76 (dd, J = 10.06 Hz, 2.16 Hz, 1H, =CH). MS (ESI): m/z 259.00 [M+H] 
+. 
N1-Acryloyl-3-methylbenzohydrazide 60i: Yield = 87%; m.p. 138-140°C; 1H NMR (DMSO-
d6): δ 10.41 (d, J = 1.41 Hz, 1H, CONH), 10.20 (d, J = 1.77 Hz, 1H, CONH), 7.67 (m, 2H, Ar-H), 
7.39 (m, 1H, Ar-H), 6.34 (q, J=17.13 Hz, 10.19 Hz, 1H, =CH), 6.22 (dd, J=17.12 Hz, 2.09 Hz, 1H, 
=CH), 5.75 (dd, J = 10.21 Hz, 2.09 Hz, 1H, =CH), 2.37 (s, 3H, CH3). MS (ESI): m/z 227.08 
[M+Na] +, 205.09 [M+H] +. 
N1-Acryloyl-2-methylbenzohydrazide 60j: Yield = 82%; m.p. 151-153°C; 1H NMR (DMSO-
d6): δ 10.18 (s, 2H, CONH), 7.38 (m, 2H, Ar-H), 7.27 (m, 2H, Ar-H), 6.33 (q, J = 17.14 Hz, 10.08 
Hz, 1H, =CH), 6.23 (dd, J = 17.15 Hz, 2.16 Hz, 1H, =CH), 5.75 (dd, J = 10.09 Hz, 2.16 Hz, 1H, 
=CH), 2.39 (s, 3H, CH3). MS (ESI): m/z 227.08 [M+Na]
 +, 205.09 [M+H] +. 
N1-Acryloyl-4-methylbenzohydrazide 60k: Yield = 79%; m.p. 157-160°C; 1H NMR (DMSO-
d6): δ 10.29 (d, J = 85.67, 2H, CONH), 7.79 (d, J = 8.17 Hz, 2H, Ar-H), 7.30 (d, J = 8.00 Hz, 2H, 
Ar-H), 6.34 (q, J = 17.16 Hz, 10.20 Hz, 1H, =CH), 6.21 (dd, J = 17.13 Hz, 2.07 Hz, 1H, =CH), 
5.75 (dd, J = 10.16 Hz, 2.10 Hz, 1H, =CH), 2.37 (s, 3H, CH3). MS (ESI): m/z 205.09 [M+H]
 +. 
N1-Acryloyl-4-methoxylbenzohydrazide 60l: Yield = 85%;  m.p. 165-166°C; 1H NMR (DMSO-
d6): δ 10.24 (d, J = 83.79 Hz, 2H, CONH), 7.87 (dd, J = 8.85 Hz, J = 4.95, 2H, Ar-H), 7.03 (dd, J 




Hz, 2.10 Hz, 1H, =CH), 5.74 (dd, J = 10.22 Hz, 2.05 Hz, 1H, =CH), 3.82 (s, 3H, OCH3). MS (ESI): 
m/z 243.07 [M+Na] +, 221.09 [M+H] +. 
N1-Acryloyl-3,4-dimethoxylbenzohydrazide 60m: Yield = 75%; m.p. 163-165°C; 1H NMR 
(DMSO-d6): δ 10.25 (brs, 2H, CONH), 7.53 (dd, J = 8.38 Hz, 1H, Ar-H), 7.47 (d, J = 2.00 Hz, 1H, 
Ar-H), 7.06 (d, J = 8.53 Hz, 1H, Ar-H), 6.35 (q, J = 17.13 Hz, 10.24 Hz, 1H, =CH), 6.22 (dd, J = 
17.12 Hz, 2.08 Hz, 1H, =CH), 5.75 (dd, J = 10.22 Hz, 2.07 Hz, 1H, =CH), 3.81 (d, J = 5.26 Hz, 
6H, 2xOCH3). MS (ESI): m/z 273.08 [M+Na]
 +, 251.10 [M+H] +. 
3.3 Scheme for the synthesis of N2-[3-(benzoylaminoamino)-1-oxopropyl]-N1-
benzoylhydrazine 61a  
 
Scheme 3.2 : Scheme for the synthesis of N2-[3-(benzoylaminoamino)-1-oxopropyl]-N1-
benzoylhydrazine 61a. 
The reaction conditions are as follows: a: ethanol, ~70-80°C, 24 h. 
3.3.1 Synthesis of N2-[3-(benzyoylaminoamino)-1-oxopropyl]-N1-benzoylhydrazine 61a 
Benzohydrazide (0.005 moles, 0.72 g) and N1-acryloylbenzohydrazide (0.005 moles, 1 g) were 
dissolved in ethanol (0.17 moles, 10 ml) and refluxed for 24 h. The reaction was monitored using 
chloroform: methanol (9.5:0.5) and the solvent was evaporated in vacuo after the completion of 
the reaction. The residues were then recrystallised from 95% ethanol.  
Yield = 69%; m.p. 193-195°C; 1H NMR (DMSO-d6): δ 10.36 (s, 1H, CONH), 10.05 (d, J = 6.23 
Hz, 1H, CONH), 9.99 (s, 1H, CONH), 7.85 (q, J = 17.95 Hz, 7.45 Hz, 4H-Ar), 7.50 (m, 6H, Ar-











Scheme 3.3 : General scheme for the synthesis of N1-aroyl-N2-acylhydrazines 62a-b. 
The reaction conditions are as follows: a: acetyl anhydride/propionic anhydride, RT, 15 min. 
62a: R = CH3 and 62b: R = CH2CH3. 
3.4.1 Synthesis of N1-acetylbenzohydrazide 62a 
Acetic anhydride (7.34 mmoles, 0.70 ml) was added dropwise to benzohydrazide (7.34 mmoles, 
1g) dissolved in ethanol (85.63 mmoles, 5 ml) and stirred at room temperature for 15 min. The 
mixture was diluted with diethyl ether, filtered and rinsed with diethyl ether. The residues were 
then recrystallised from 95% ethanol.  
Yield = 83% ; m.p.171-172°C (lit. m.p. 174°C);116 1H NMR (DMSO-d6): δ 10.28 (s, 1H, CONH), 
9.88 (s, 1H, CONH), 7.86 (m, 2H, Ar-H), 7.58 (m, 1H, Ar-H), 7.50 (m, 2H, Ar-H), 1.91 (s, 3H, 
CH3). 
13C NMR (DMSO-d6): 168.84, 165.74, 132.60, 131.96, 128.60, 127.54, 20.72. MS (ESI): 
m/z 217.04 [M+K] +, 179.07 [M+H] +. 
3.4.2 Synthesis of N1-propionylbenzohydrazide 62b 
Propionic anhydride (7.34 mmoles, 0.95 ml) was added dropwise to benzohydrazide (7.34 mmoles, 
1g) dissolved in ethanol (85.63 mmoles, 5 ml) and stirred at room temperature for 15 min. The 
mixture was diluted with diethyl ether, filtered and rinsed with diethyl ether. The residues were 
then recrystallised from 95% ethanol. 
Yield = 87%;  m.p.106-107°C (lit. m.p.110°C);116 1H NMR (DMSO-d6): δ 10.29 (s, 1H, CONH), 
9.84 (s, 1H, CONH), 7.86 (m, 2H, Ar-H), 7.58  (m, 1H, Ar-H), 7.50 (t, 2H, Ar-H), 2.19 (q, 2H, 
CH2), 1.06 (t, 3H, CH3). 
13C NMR (DMSO-d6): 172.68, 165.77, 132.67, 131.92, 128.46, 127.54, 




3.5 General scheme for the synthesis of 3,5-bis(arylidene)-4-piperidone derivatives 63a-f 
 
Scheme 3.4 : General scheme for the synthesis of 3,5-bis(arylidene)-4-piperidones 63a-f. 
The following reaction conditions were used: a: HCl/CH3COOH, RT, followed by treatment with 
K2CO3 (25% w/v). 63a: R = H, 63b: R = Cl, 63c: R = F, 63d: R = NO2, 63e: R = OCH3, 63f: R = 
CH3. 
3.5.1 Synthesis of 3,5-bis(benzylidene)-4-piperidone derivatives 63a-f 
The synthesis of 63a-f was carried out as previously described in the literature.64 Briefly, the 
appropriate aryl aldehyde (26.71 mmoles, 2.72 ml) was added to a suspension of 4-piperidone 
hydrochloride monohydrate (13.03 mmoles, 2 g) in acetic acid (35 ml) and dry hydrogen chloride 
was passed through it for 0.5 h until a clear solution was obtained. It was stirred at room 
temperature for 24 h. The precipitate was collected, added to a mixture of saturated aqueous 
potassium carbonate solution (25% w/v, 25 ml) and acetone (25 ml) and stirred for 0.5 h. The free 
base obtained was washed with water (50 ml), dried and further used without purification except 
63a was recrystallized from 95% ethanol and used for biological experiments. 
3,5-Bis(benzylidene)-4-piperidone 63a: Yield = 86%; m.p. 175-177°C (lit. m.p.177-178°C);64 1H 
NMR (DMSO-d6): δ 7.82 (brs, 2H, =CH), 7.40 (m, 10H, Ar-H), 4.16 (d, J= 1.73 Hz, 4H, piperidyl 
H). The NH peak was not observed.  
3,5-Bis(4-Chlorobenzylidene)-4-piperidone 63b: Crude yield = 64%; 1H NMR (DMSO-d6): δ 
7.55 (brs, 2H, =CH), 7.52 (s, 8H, Ar-H), 3.96 (d, J = 1.33, 4H, piperidyl H). The NH peak was not 
observed. 
3,5-Bis(4-Fluorobenzylidene)-4-piperidone 63c: Crude yield = 40%; 1H NMR (DMSO-d6): δ 
7.56 {d, J = 8.94 Hz, 6H (4H, Ar-H; 2H, =CH)}, 7.30 (m, 4H, Ar-H), 3.96 (s, 4H, piperidyl H). 




3,5-Bis(4-Nitrobenzylidene)-4-piperidone 63d: Crude yield = 94%; 1H NMR (DMSO-d6): δ 8.28 
(d, J = 7.48 Hz, 4H, Ar-H), 7.76 (d, J = 7.57 Hz, 4H, Ar-H), 7.66 (s, 2H, =CH), 4.02 (s, 4H, 
piperidyl H). The NH peak was not observed. 
3,5-Bis(4-Methyoxybenzylidene)-4-piperidone 63e: Crude yield = 73%; 1H NMR (DMSO-d6): 
δ 7.53 (s, 2H, =CH), 7.44 (s, 4H, Ar-H), 7.02 (s, 4H, Ar-H), 3.96 (s, 4H, piperidyl H), 3.8 (s, 6H, 
2xOCH3). The NH peak was not observed. 
3,5-Bis(4-Methylbenzylidene)-4-piperidone 63f: Crude yield = 72%; 1H NMR (DMSO-d6): δ 
7.66 (brs, 2H, =CH), 7.40 (d, 4H, J = 7.85 Hz, Ar-H), 7.30 (d, 4H, J = 7.77 Hz, Ar-H), 4.15 (s, 4H, 
piperidyl H), 2.35 (s, 3H, CH3). The NH peak was not observed. 
3.6 Scheme for the attempted synthesis of 3,5-bis(benzylidene)-1-[3-
(arylcarbonylaminoamino)-3-oxo-1-propyl]-4-piperidone 64a 
 





The reaction conditions are as follows: a: dichloromethane (CH2Cl2,) ~80°C, 24 h; b: ethanol, 
benzohydrazide, ~80°C, 24 h; c: triethylamine (TEA), CH2Cl2, RT, 24 h; d: benzaldehyde, 
HCl/CH3COOH, RT, 24 h.  
3.6.1 Synthesis of methyl-3-[3,5-bis(benzylidene)-4-oxo-1-piperidinyl]-propanoate 63g 
Compound 63a (5.45 mmoles, 1.5 g) was dissolved in chloroform and methanol (40 ml: 10 ml). 
Methyl acrylate (5.45 mmoles, 0.58 ml + 10% excess) was added dropwise to this solution and 
was stirred at 80°C for 17 h. Chloroform and methanol (9.5:0.5) was used as the TLC solvent 
system to monitor the reaction. The solvent was evaporated after completion of the reaction and 
yellow residues were obtained. 
Yield = 60%; 1H NMR (CDCl3): δ 7.83 (s, 2H, =CH), 7.41(m, 10H, Ar-H), 3.87 (d, J = 1.51 Hz, 
4H, piperidyl H), 3.61 (s, 3H, OCH3), 2.90 (t, J = 7.26 Hz, 14.52 Hz, 2H, CH2), 2.46 (t, J = 7.24 
Hz, 14.48 Hz, 2H, CH2). 
3.6.2 Synthesis of N2-benzoyl-N1-3-[4-oxo-1-piperidinyl]-1-oxopropyl-hydrazine 63h 
The 4-piperidone monohydrate hydrochloride (7.89 mmoles, 1.21 g) was condensed with N1-
acryloyl benzohydrazide (5.25 mmoles, 1 g) in the presence of triethylamine (36.4 mmoles, 3.64 
g) in dichloromethane (10 ml) at room temperature for 24 h. Chloroform and methanol (9.5:0.5) 
were used as solvent to monitor the completion of the reaction using TLC. The solvent was 
evaporated in vacuo and the product was obtained. 
Yield = 53%; 1H NMR (DMSO-d6): δ 7.84 (m, 2H, Ar-H), 7.56 (m, 1H, Ar-H), 7.49 (m, 2H, Ar-
H), 2.93 (t, J = 6.06 Hz, 12.11 Hz, 4H, piperidyl H), 2.73 (t, J = 5.75 Hz, J = 11.51 Hz, 2H, CH2), 
2.35 (t, J = 6.14 Hz, 12.18 Hz, 4H, piperidyl H), 2.23 (t, J = 6.11 Hz, J = 12.21 Hz, 2H, CH2).The 
NH peak was not observed. 
The attempt was made to synthesize compound 64a from 63g and 63h intermediates following the 
reaction conditions as indicated in scheme 3.5. However, despite many efforts, the synthesis of 
3,5-bis(benzylidene)-1-[3-(arylcarbonylaminoamino)-3-oxo-1-propyl]-4-piperidone 64a did not 




3.7 General scheme for the synthesis of 3,5-bis(benzylidene)-1-[3-
(arylcarbonylaminoamino)-3-oxo-1-propyl]-4-piperidone derivatives 64a-g 
 
Scheme 3.6 : General scheme for the synthesis of 3,5-bis(benzylidene)-1-[3-
(arylcarbonylaminoamino)-3-oxo-1-propyl]-4-piperidones 64a-g. 
The following reaction conditions were used: a: Et3N, CH2Cl2: methanol (2:1), ~80°C for 24 h. 
64a: R = H, R1 = R2 = H, 64b: R = H, R1 = R2 = OCH3, 64c: R = Cl, R1 = R2 = OCH3, 64d: R = 
NO2, R1 = R2 = OCH3, 64e: R = F, R1 = R2 = OCH3, 64f: R = OCH3, R1 = R2 = OCH3, 64g: R = 
CH3, R1 = R2 = OCH3. 
3.7.1 Synthesis of 3,5-bis(benzylidene)-1-[3-(arylcarbonylaminoamino)-3-oxo-1-propyl]-4-
piperidones 64a-g 
3,5-Bis(benzylidene)-4-piperidone 63a (0.0036 moles, 1 g) was condensed with N1-
acryloylbenzohydrazide 60a (0.011 moles, 2.071 g) in the presence of triethylamine (0.018 moles, 
1.84 g) in dichloromethane (10 ml) and methanol (5 ml) at ~80°C for 24 h. Chloroform and 
methanol (9.5:0.5) were used as the solvent to monitor the completion of the reaction using TLC. 
The solvent was evaporated in vacuo and the product was recrystallized from 95% ethanol. 
3,5-Bis(benzylidene)-1-[3-(phenylcarbonylaminoamino)-3-oxo-1-propyl]-4-piperidone 64a 
Yield = 81%; m.p. 154-156°C; 1H NMR (DMSO-d6): δ 10.34 (s, 1H, CONH), 9.92 (s, 1H, CONH), 
7.83 (d, J = 7.82, 2H, Ar-H), 7.62 (s, 2H, =CH), 7.55 (d, J = 8.45 Hz, 5H, Ar-H), 7.48 (dd, J = 
7.79, 5H, Ar-H), 7.44 (m, 3H, Ar-H), 3.88 (s, 4H, piperidyl H), 2.87 (t, J = 7.02 Hz, J = 14.05 Hz, 







piperidone 64b  
Yield = 86%; m.p. 151-154°C; 1H NMR (DMSO-d6): δ 10.20 (s, 1H, CONH), 9.86 (s, 1H, CONH), 
7.62 (s, 2H, =CH), 7.55 (d, J = 7.31 Hz, 4H, Ar-H), 7.5 (m, 6H, Ar-H), 7.43 (m, 2H, Ar-H), 7.02 
(d, J = 8.51 Hz, 1H, Ar-H), 3.88 (s, 4H, piperidyl H), 3.79 (d, J = 13.42 Hz, 6H, 2xOCH3), 2.87 (t, 
J = 6.85 Hz, J = 13.70 Hz, 2H, CH2), 2.39 (t, J = 6.94 Hz, J = 13.91 Hz, 2H, CH2). MS (ESI): m/z 
526.23 [M+H] +. 
3,5-Bis(4-chlorobenzylidene)-1-[3-(3,4-dimethoxyphenylcarbonylaminoamino)-3-oxo-1-
propyl]-4-piperidone 64c 
Yield = 76%; m.p. 200-202°C; 1H NMR (DMSO-d6): δ 10.21 (s, 1H, CONH), 9.86 (s, 1H, CONH), 
7.59 (s, 2H, =CH), 7.55 (q, J = 21.20 Hz, 8H, Ar-H), 7.48 (dd, J = 8.47, 1H, Ar-H), 7.43 (d, J = 
1.86 Hz, 1H, Ar-H), 7.03 (d, J = 8.52 Hz, 1H, Ar-H), 3.85 (s, 4H, piperidyl H), 3.79 (d, J = 12.07 
Hz, 6H, 2xOCH3), 2.87 (t, J = 6.88 Hz, 2H, CH2), 2.34 (t, J = 6.83 Hz, 2H, CH2). MS (ESI): m/z 
594.15, 595.15 [M+H] +, 596.15 [M+2H] +. 
3,5-Bis(4-fluorobenzylidene)-1-[3-(3,4-dimethoxyphenylcarbonylaminoamino)-3-oxo-1-
propyl]-4-piperidone 64d 
Yield = 80%; m.p.198-200°C; 1H NMR (DMSO-d6): δ 10.21 (s, 1H, CONH), 9.86 (s, 1H, CONH), 
{m, 6H (4H, Ar-H; 2H, =CH)}, 7.5 (dd, J = 8.42 Hz, 1H, Ar-H), 7.43 (d, J = 1.85 Hz, 1H, Ar-H), 
7.31 (t, J = 8.81 Hz, 4H, Ar-H), 7.03 (d, J = 8.56 Hz, 1H, Ar-H), 3.85 (s, 4H, piperidyl H), 3.79 (d, 
J = 12.47 Hz, 6H, 2xOCH3), 2.87 (t, J = 6.94 Hz, 2H, CH2), 2.4 (t, J = 6.91 Hz, 2H, CH2). MS 
(ESI): m/z 562.21 [M+H] +. 
3,5-Bis(4-nitrobenzylidene)-1-[3-(3,4-dimethoxyphenylcarbonylaminoamino)-3-oxo-1-
propyl]-4-piperidone 64e 
Yield = 71%; m.p. 153-158°C; 1H NMR (DMSO-d6): δ 10.22 (s, 1H, CONH), 9.87 (s, 1H, CONH), 
8.29 (d, J = 8.76 Hz, 4H, Ar-H), 7.82 (d, J = 8.78 Hz, 2H, Ar-H), 7.77 (d, J = 8.78 Hz, 2H, Ar-H), 
7.69 (d, J = 20.10 Hz, 2H, =CH), 7.48 (dd, J = 8.45 Hz, 10.38 Hz, 1H, Ar-H), 7.43 (d, J = 1.84 Hz, 
1H, Ar-H), 7.02 (d, J = 8.55 Hz, 1H, Ar-H), 4.02 (s, 2H, piperidyl H), 3.92 (s, 2H, piperidyl H), 
3.79 (d, J = 13.91 Hz, 6H, 2xOCH3), 2.88 (t, J = 6.78 Hz, 13.56 Hz, 2H, CH2), 2.39 (t, J = 6.78 







Yield = 75%; m.p. 175-178°C; 1H NMR (DMSO-d6): δ 10.21 (s, 1H, CONH), 9.88 (s, 1H, CONH), 
7.56 (s, 2H, =CH), 7.50 (d, J = 8.88 Hz, 4H, Ar-H), 7.45 (m, 2H, Ar-H), 7.036 (m, 4H, Ar-H), 7.02 
(s, 1H, Ar-H), 3.84 (s, 3H, OCH3), 3.81 (s, 6H, 2xOCH3), 3.80 (s, 4H, piperidyl H), 3.77 (s, 3H, 
OCH3), 2.88 (t, J = 6.9 Hz, 13.80 Hz, 2H, CH2), 2.41 (t, J = 6.88 Hz, 13.76 Hz, 2H, CH2). MS 
(ESI): m/z 586.25 [M+H] +. 
3,5-Bis(4-methylbenzylidene)-1-[3-(3,4-dimethoxyphenylcarbonylaminoamino)-3-oxo-1-
propyl]-4-piperidone 64g 
Yield = 82%; m.p. 190-192°C; 1H NMR (DMSO-d6): δ 10.20 (s, 1H, CONH), 9.86 (s, 1H, CONH), 
7.58 (s, 2H, =CH), 7.48 (dd, J = 8.37 Hz, 1H, Ar-H), 7.43 (m, 5H, Ar-H), 7.3 (d, J = 8.09 Hz, 4H, 
Ar-H), 7.02 (d, J = 8.54 Hz, 1H, Ar-H), 3.85 (s, 4H, piperidyl H), 3.79 (d, J = 13.07 Hz, 6H, 
2xOCH3), 2.86 (t, J = 7.04 Hz, 2H, CH2), 2.38 (t, J = 7.14 Hz, 2H, CH2), 2.35 (s, 6H, CH3). MS 

















CHAPTER 4 : BIOLOGICAL EVALUATIONS 
4.1 Materials and Reagents 
The human colon cancer cell line HCT 116 and human CRL-1790 normal colon cell line were 
purchased from the ATCC whereas the breast cancer cell lines MCF-7 and MDA-MB-231 were 
obtained from the Saskatchewan Cancer Agency. All the media and reagents were purchased from 
HyClone unless specified otherwise. HCT 116 cells were cultured in McCoy’s 5A media, whereas 
minimum essential media (EMEM) obtained from the ATCC was used to culture CRL-1790 cells. 
For MCF-7 and MDA-MB-231 cells, DMEM media with a high concentration of glucose was 
used. Each of the culture media was supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin-streptomycin antibiotics. All the cell lines were grown in an atmosphere of 95% O2 and 
5% CO2 at 37°C in an incubator. 
All the chemicals were purchased from Sigma unless specified otherwise. Dimethyl sulfoxide 
(DMSO), 50% w/v trichloroacetic acid (TCA), 0.4% w/v sulforhodamine B (SRB) in 1% v/v acetic 
acid, 1% v/v acetic acid, 10 mM tris[hydroxymethyl]aminomethane buffer (TRIS base). 2′,7′-
dichlorofluorescin diacetate (DCF-DA) was used for the ROS determination. The 
tetramethylrhodamine ethyl ester (TMRE) dye was purchased from Cayman Chemical which is 
used in the mitochondrial membrane potential study. 
4.2 Antiproliferation assay using the sulforhodamine B dye 
This assay was performed to determine the cytotoxicity of various compounds towards neoplastic 
(HCT 116, MCF-7 and MDA-MB-231) cells and non-malignant colon CRL-1790 cells. The SRB 
dye was used for quantitative measurement of cell numbers after treatment with the compounds. 
This assay was performed as previously described in the literature.117 In brief, 5000 cells were 
plated per 100 µL of media at a concentration of 5 x 104 cells/mL in each well of a 96-well plate 
and kept in an incubator at 37°C and 5 % CO2 for 24 h. On the next day, the control plate Tz, 
which is without the addition of any compound was treated with 25 µL of 50% w/v trichloroacetic 
acid (TCA) and incubated at 4°C for 1 h and the plate was washed with water four times and 
allowed to dry at room temperature. After 24 h, in the test plate Tc, the cytotoxic agents were 
added in different concentrations and incubated for 48 h. Each plate consisted of positive controls 
(5-FU and melphalan) and a negative control (only DMSO). After 48 h, 50 µL of 50% w/v 




h, the plates were washed with water four times and allowed to dry at room temperature for 24 h. 
100 µL of sulforhodamine B solution was added to each well and stained at room temperature for 
15 min then washed with 1% acetic acid about 4-5 times and kept at room temperature to dry for 
24 h. The SRB dye was solubilized by the addition of 200 µL of 10 mM Trizma base solution to 
each well and the plate was kept in a microplate shaker for 5 min (room temperature 25 °C, 100 
rpm) and the absorbance measured at 515 nm using a microplate reader. The optical density (OD) 
of SRB in each well is directly proportional to the cell number and therefore cell growth can be 
calculated using the following formula: 




where, ODtest is the optical density of the test well after 48 h drug exposure. 
ODDMSO is the optical density of the negative control (DMSO). 
ODcontrol is the optical density of untreated well at day 0.  
Each experiment was carried out in triplicate on three different occasions. Initial screening of the 
compounds towards HCT 116, MCF-7 and MDA-MB 231 cell lines was carried out at two 
different concentrations of 100 µM and 10 µM such that the final concentration of DMSO in each 
well is less than 1%. For IC50 determinations, the concentration ranged from 100 µM to 0.001 µM.  
In another assay performed by our collaborators in Japan, compounds 60a-m, 61a and 62a-b were 
also evaluated against HSC-2, HSC-3 and HSC-4 human squamous cell carcinomas as well as 
human promyelocytic leukemia HL-60 cells in addition to human non-malignant human gingival 
fibroblasts (HGF), human pulp cells (HPC) and human periodontal ligament fibroblasts (HPLF). 
The assay was undertaken using a literature method118 except the incubation time was 48 h. 
Different concentrations (maximum of 400 μM) of each compound were added to the cultured 
cells and incubated for 48 h at 37°C. The cytotoxic concentration (CC50) values were determined 
from dose-response curves.  
Another cytotoxicity study was conducted by our collaborators in El Paso wherein compounds 
60a-m, 61a and 62a-b were evaluated against various leukemic cells (Ramos, NALM-60, CEM, 
HL-60, JURKAT and RAJI) and normal cells (Hs27 and MCF10A) as described previously in the 




malignant and non-malignant cells grown in either DMEM or RPMI media, followed by 
incubation at 37℃ for 24 h. The average cytotoxic potencies of three independent experiments, 
expressed as the concentration required for 50% of cell death (CC50 values) were obtained.  
4.3 Combinatorial approach using HCT 116 cells 
In this experiment, N1-acryloyl-3,4-dimethoxylbenzohydrazide 60m was used as a potential 
chemosensitizer of HCT 116 cells to 3,5-bis(benzylidene)-4-piperidone 63a. 5-FU (3.0 µM) was 
used as a positive control and only DMSO was used as a negative control. In this study, 
approximately 1.2 x 106 cells were cultured in T75 flasks and kept in an incubator at 37°C and 5 % 
CO2 for 24 h. Different solutions were prepared in DMSO such that the final concentration of 
DMSO in each flask is less than 1%. These solutions consisted of 60m (5 µM, 10 µM and 15 µM), 
5-FU (3.0 µM), 63a (0.1 µM, 0.2 µM and 0.4 µM) in each tube along with 7.5 ml media. After 24 
h, the media was aspirated and fresh media containing different cytotoxic agents with varying 
concentrations were added to each of the T75 flasks and kept in an incubator for 48 h. In tandem 
with these compounds, other T75 flasks were treated with 60m (5 µM, 10 µM and 15 µM) and kept 
in an incubator for next 24 h. After 24 h, each of these flasks were treated with different 
concentrations of 63a (0.1 µM, 0.2 µM and 0.4 µM) and 5-FU (3.0 µM) and kept in an incubator 
for the next 24 h. The following day, the media was aspirated and trypsin was added to each flask 
and kept in an incubator for one minute. Fresh media was added to each flask which was 
centrifuged at 1000 rpm for 5 min at 4°C. Following centrifugation, the supernatant was removed 
and fresh media was added to the cell pellet, mixed thoroughly and then a solution was prepared 
consisting of 50 µL of cells in the media and 50 µL of trypan blue and live cells were counted 
using an automated cell counter.  
Simultaneously, a cytotoxic assay was performed using SRB dye, as per the procedure mentioned 
previously. Herein, the addition of compounds at different times is the same as that carried out in 





4.4 Studies on mechanisms of action 
4.4.1 Mitochondrial membrane potential (Δψm) 
The main intention to conduct this assay was to measure the effect of cytotoxic agents (60m, 64a, 
64e and 64g) on mitochondrial membrane potential. In this study, TMRE (tetramethylrhodamine 
ethyl ester), a fluorescent lipophilic cationic dye, was used to monitor changes in Δψm. HCT 116 
cells (5x103 cells/well) were cultured in 96 well optical-bottom plates and kept in an incubator at 
37 °C and 5 % CO2 for 24 h for proper adherence. Compounds were dissolved in DMSO at a 
concentration of 10 mM while in the case of 5-FU, a concentration of 40 mM was used. Further 
dilutions were made in the media such that the final concentration does not exceed more than 1% 
DMSO. After 24 h, the cells were treated with the IC50 concentrations of 60m, 64a, 64e, 64g and 
5-FU and incubated for 48 h. CCCP and 2,4-DNP were used as the positive controls with a final 
concentration of 50 µM. After 48 h, 20 µL of CCCP and 2,4-DNP were added to the cell plate and 
incubated for 30 min. The TMRE dye was prepared in DMSO as a stock solution at a concentration 
of 25 mM and the final concentration added to the cell plate was 500 nM. 20 µL of a solution of 
the TMRE dye was added to each well and the plate was incubated for another 30 min at 37°C and 
in an atmosphere of 5 % CO2. 
After incubation, the cells were centrifuged at 400 x g for 5 min at room temperature and then the 
media was removed. 200 µL of phosphate buffered saline (PBS) was added to each well and again 
the cells were centrifuged. The supernatant was aspirated and this process was repeated once for 
the complete removal of excess of the dye. 100 µL of phosphate buffered saline (PBS) was added 
to each well and the fluorescence was measured at excitation and emission wavelengths at 530 nm 
and 590 nm respectively. Fluorescence was measured using a BioTek plate reader. After the 
reading were taken, 25 µL of 50% w/v TCA was added to each well and kept in a refrigerator for 
1 h. The plates were washed with water four times and allowed to air dry. Next day, 100 µL of 0.4 
% SRB solution was added to each well, incubated at room temperature for 10 min and washed 
four times with 1% acetic acid and allowed to air dry for a day. 200 µL of 10 mM Trizma base 





4.4.2 Evaluation of reactive oxygen species (ROS) levels 
The main purpose of this assay was to evaluate the effect of cytotoxic agents (60m, 64a, 64e and 
64g) on ROS levels. In this study, the 2′,7′-dichlorofluorescein diacetate (DCF-DA) dye was used 
to measure reactive oxygen species activity within the cells. HCT 116 cells were cultured in a 96 
well optical-bottom plates with a seeding density of 5,000 cells/well and kept in an incubator at 
37°C and 5 % CO2 for 24 h for the proper attachment of the cells. Compounds were dissolved in 
DMSO using a concentration of 10 mM and 5-FU at 40 mM. Further dilutions were made in the 
media such that the final concentration does not exceed more than 1% DMSO. After 24 h, the cells 
were treated with the IC50 concentrations of 60m, 64a, 64e, 64g and 5-FU and incubated for 48 h. 
Hydrogen peroxide was used as a positive control with a final concentration of 10 µM. After 48 h, 
30 µL of H2O2 was added and incubated at 37°C and 5 % CO2  for 30 min. Then 60 µL of the DCF-
DA dye was added to each well with a final concentration of 30 µM and kept in an incubator for 
30 min at 37°C and 5 % CO2. After incubation, the cells were centrifuged at 400 x g at room 
temperature for 5 min and the media was removed. The cells were then washed once with 100 µL 
of PBS and the supernatant was aspirated. Finally, 100 µL of PBS was added to each well and the 
fluorescence was measured at the excited and emission wavelengths of 485 nm and 530 nm, 
respectively. A BioTek spectrometer was used to measure the fluorescence intensity.   
4.5 Statistical analysis 
All the data points are represented as the mean ± SD wherein the standard deviation was used for 
replicates of three independent experiments. Statistical analysis was carried out using either one-
way or two-way ANOVA. One-way ANOVA with Dunnett’s multiple comparison post-hoc 
analysis was used to determine the significance between the control and test groups. For the 
combination approach experiments, a two-way ANOVA was carried out. A p value below 0.05 






CHAPTER 5 : RESULTS 
5.1 Assessment of cytotoxicity using sulforhodamine B (SRB) 
The purpose of this experiment is to determine the potency of cytotoxic agents towards carcinoma 
cells such as HCT 116, MCF-7 and MDA-MB-231 neoplasms and against normal cells such as 
colon CRL-1790 cells. This assay is based on the use of the SRB dye that binds under mild acidic 
conditions to the proteins present in the trichloroacetic acid-fixed cells in the plate and the dye is 
extracted and solubilized with Trizma base under mild basic conditions to measure the cell density 
quantitatively. The IC50 values were obtained by plotting a graph of the log concentrations against 
the percentage inhibition using Graph Pad Prism software. A sigmoidal graph was obtained and 
the IC50 values were determined at a concentration when there is 50% of growth inhibition. Three 
independent experiments were conducted with three replicates in each experiment. 
5.1.1 Antiproliferation assay using HCT 116 colon cancer cells and CRL-1790 normal colon 
cells 
The initial screening of the compounds 60a-m, 61a and 62a-b was carried out using concentrations 
of 100 µM and 10 µM in HCT 116 cells. The results in Table 5.1 reveal that 60m showed more 
than 47% inhibition at 10 µM concentration and therefore it’s IC50 value was determined using 
different concentrations ranging from 100 µM to 0.01 µM. 5-FU and melphalan were used as the 
positive controls in each experiment and their IC50 values were measured using concentrations 
ranging from 0.01 µM to 100 µM. The IC50 value of 63a was also obtained which is later used in 
a combinational approach with 60m. To study the structure-activity relationships, the IC50 values 
of 59a, 59m, 60a and 62b were determined. For compounds 64a-g, the cytotoxic assay was 
performed using a concentration range of 0.01 µM to 100 µM. 
Based on the calculated IC50 values as seen in Table 5.2, the benzohydrazides 59a and 3,4-
dimethoxybenzohydrazide 59m did not show any noticeable toxicity against HCT 116 cancer 
colon cells or CRL-1790 normal colon cells. N1-Acryloylbenzohydrazide 60a and N1-acryloyl-
3,4-dimethoxybenzohydrazide 60m showed some potency against HCT 116 cells but had little or 
no effect on CRL-1790 cells. The saturated compound 62b did not show any marked toxicity 




Compound 63a showed remarkable potency compared to the standard drugs 5-FU and melphalan. 
The results from Table 5.3, reveal that all of the compounds 64a-g are potent cytotoxins against 
HCT 116 cells and showed inhibition against normal CRL-1790 cells. In particular, 64e has a IC50 
value of 0.283 µM towards HCT 116 cells which is approximately 15 times more potent than the 
standard drug 5-FU.  
 
Table 5.1 : Screening of 60a-m, 61a, 62a-b against HCT 116 cells 
Compound Substituents % inhibition at 100 µM % inhibition at 10 µM 
60a H 94.13 ± 1.44 10.53 ± 1.70 
60b 4-F 60.66 ± 3.22 -2.35 ± 2.24 
60c 4-Br 87.90 ± 0.91 -3.28 ± 1.50 
60d 4-Cl 82.31 ± 0.80 -5.05 ± 2.36 
60e 2-Cl 75.73 ± 1.65 4.30 ± 1.38 
60f 3-Cl 95.71 ± 1.71 13.45 ± 1.79 
60g 3,4-Cl2 >100 6.72 ± 1.97 
60h 2,5-Cl2 87.67 ± 1.62 7.12 ± 1.51 
60i 3-CH3 93.89 ± 3.35 15.43 ± 2.13 
60j 2-CH3 62.05 ± 2.48 10.36 ± 1.61 
60k 4-CH3 >100 11.52 ± 2.99 
60l 4-OCH3 85.07 ± 3.28 8.62 ± 2.79 
60m 3,4-(OCH3)2 97.94 ± 1.92 46.89 ± 2.55 
61a -- 96.99 ± 1.86 18.56 ± 3.98 
62a CH3 13.64 ± 3.03 -4.89 ± 2.52 
62b CH2CH3 9.35 ± 2.53 -10.47 ± 2.93 
5-FU -- 94.12 ± 0.96 84.76 ± 2.53 





Further to confirm the functional group contributing towards cytotoxicity, it was decided that IC50 
values should be determined for 59a, 59m and 62b. Also compound 60m showed higher growth 
inhibition as compared to other compounds in the series 60 at 10 µM concentration, and thus the 
decision was made to determine its IC50 value along with the unsubstituted compound 60a.  
  
Table 5.2 : Evaluation of 59a, 59m, 60a, 60m, 62b and 63a against HCT 116 cells and CRL-
1790 cells 
a *SD = Standard deviation.  




Mean IC50 (µM) ± *SDa 
against HCT 116 
cancer cells 





59a H >100 >100 ~1.00 
59m 3,4 (OCH3)2 >100 >100 ~1.00 
60a H 36.95 ± 2.84 >100 >2.70 
60m 3,4 (OCH3)2 15.27 ± 0.42 >100 >6.55 
62b CH2CH3 >100 >100 ~1.00 
63a H 0.37 ± 0.06 13.46 ± 1.99 36.38 
5-FU -- 3.77 ± 0.48 10.99 ± 1.43 2.92 





 Table 5.3 : Evaluation of 64a-g against HCT 116 cells and CRL-1790 cells 
a *SD = Standard deviation.  











Substituents Mean IC50 (µM) ±
*SDa 
against HCT 116 
cancer cells 





R R1 = R2 
64a H H 1.38 ± 0.25 12.31 ± 1.09 3.87 
64b H OCH3 3.15 ± 0.33 9.63 ± 1.62 3.06 
64c Cl OCH3 3.40 ± 0.01 12.23 ± 1.22 3.60 
64d F OCH3 3.82 ± 0.11 11.41 ± 2.22 2.99 
64e NO2 OCH3 0.28 ± 0.009 4.57 ± 0.53 16.32 
64f OCH3 OCH3 2.87 ± 0.23 11.07 ± 0.52 3.86 
64g CH3 OCH3 1.94 ± 0.18 9.24 ± 0.52 4.76 
5-FU -- 4.11 ± 0.22 10.84 ± 1.64 2.64 
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Figure 5.1 : a. Anti-proliferative assay of 60m against HCT 116 cells. b. Anti-proliferative assay 
of 63a against HCT 116 cells. c. Anti-proliferative assay of 64e against HCT 116 cells. d. Anti-
proliferative assay of 5-FU against HCT 116 cells. e. Anti-proliferative assay of melphalan against 
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5.1.2 Antiproliferation assay using MCF-7 cells 
MCF-7 cells are estrogen and progesterone receptors positive. The initial screening of the 
compounds (60a-m, 61a, and 62a-b) was carried out at 100 µM and 10 µM towards MCF-7 cells. 
Compounds 60j, 60k, 60l displayed promising inhibition at 10 µM concentration and thus the IC50 
values of those selected compounds were obtained. 5-FU and melphalan were used as the reference 
drugs. 
 
Table 5.4 : Screening of 60a-m, 61a, 62a-b against MCF-7 malignant cells 
Compound Substituents % inhibition at 100 µM % inhibition at 10 µM 
60a H 51.11 ± 2.87 5.47 ± 3.52 
60b 4-F 33.21 ± 3.13 -40.14 ± 3.34 
60c 4-Br 46.64 ± 3.35 -4.68 ± 3.17 
60d 4-Cl 55.90 ± 2.82 3.59 ± 2.08 
60e 2-Cl 75.83 ± 2.76 8.66 ± 1.81 
60f 3-Cl 85.85 ± 2.70 -15.50 ± 3.38 
60g 3,4-Cl2 97.39 ± 2.60 -50.47 ± 3.27 
60h 2,5-Cl2 54.16 ± 3.42 14.74 ± 3.68 
60i 3-CH3 44.19 ± 2.96 -82.81 ± 3.48 
60j 2-CH3 100.84 ± 1.39 53.25 ± 3.07 
60k 4-CH3 >100 55.31 ± 3.05 
60l 4-OCH3 99.41 ± 2.34 60.61 ± 3.29 
60m 3,4-(OCH3)2 100.99 ± 2.49 -16.10 ± 3.51 
61a --- 97.99 ± 2.68 16.05 ± 3.55 
62a CH3 -58.68 ± 3.24 -93.81 ± 4.15 
62b CH2CH3 -5.69 ± 2.54 -19.63 ± 3.66 
5-FU -- 99.32 ± 2.87 91.23 ± 3.03 




Table 5.5 indicates the cytotoxicity of 60j, 60k and 60l against MCF-7 and CRL-1790 cells. All 
three compounds are cytotoxic against MCF-7 cells. These compounds are selectively toxic to 
MCF-7 cells and showed weak growth inhibition against non-malignant CRL-1790 cells.  
Table 5.5 : Evaluation of 60j, 60k, 60l against MCF-7 malignant cells and CRL-1790 non-
malignant cells 
a *SD = Standard deviation.  












Mean IC50 (µM) ±*SDa 
against MCF-7 cancer cells 
Mean IC50 (µM) ±*SDa against 
CRL-1790 non-malignant cells 
Selectivity 
Indexb  
60j 9.14 ± 1.31 >100 >10.94 
60k 5.54 ± 0.51 >100 >18.05 
60l 3.18 ± 0.53 >100 >31.45 
5-FU 2.00 ± 0.25 10.84 ± 1.64 5.42 




5.1.3 Antiproliferation assay using MDA-MB-231 cells 
MDA-MB-231 cells are triple negative (estrogen, progesterone and HER2 negative). Since a few 
compounds showed promising activity against MCF-7 cells, we conducted the screening of the 
60a-m, 61a, 62a-b at 100 µM and 10 µM towards MDA-MB-231 cells. The data are expressed as 
the percentage growth inhibition in Table 5.6. 5-FU and melphalan were used as the reference 
drugs. 
 
Table 5.6 : Screening of 60a-m, 61a, 62a-b against MDA-MB-231 malignant cells 
Compound Substituents % inhibition at 100 µM % inhibition at 10 µM 
60a H 52.08 ± 2.04 -12.13 ± 1.50 
60b 4-F 39.88 ± 2.51 -7.37 ± 1.52 
60c 4-Br 88.76 ± 1.26 -16.52 ± 1.45 
60d 4-Cl 49.12 ± 2.04 -12.17 ± 4.05 
60e 2-Cl 91.89 ± 4.53 -7.15 ± 2.29 
60f 3-Cl 98.72 ± 0.92 15.58 ± 3.14 
60g 3,4-Cl2 >100 -19.37 ± 3.01 
60h 2,5-Cl2 >100 -5.95 ± 4.21 
60i 3-CH3 53.23 ± 2.89 -5.91 ± 3.86 
60j 2-CH3 46.79 ± 3.63 -2.64 ± 2.37 
60k 4-CH3 74.63 ± 2.96 -8.78 ± 1.52 
60l 4-OCH3 47.76 ± 3.19 -4.95 ± 3.12 
60m 3,4-(OCH3)2 50.50 ± 1.42 -15.89 ± 1.96 
61a --- 95.66 ± 4.22 -16.00 ± 2.91 
62a CH3 -15.30 ± 3.46 -22.65 ± 2.65 
62b CH2CH3 -11.53 ± 2.52 -25.27 ± 1.82 
5-FU -- >100 17.43 ± 2.97 




Table 5.7, indicates the cytotoxicity of reference compounds against MDA-MB-231 and CRL-
1790 cells. Both compounds showed weak potency against MDA-MB-231 cells at 10 µM. These 
reference compounds are not selective as they showed little or no inhibition of the growth of MDA-
MB-231 cells. The IC50 values of 60a-m were not determined. 
Table 5.7 : Evaluation of reference drugs 5-FU and melphalan against MDA-MB-231 cancer 
cells and non-malignant CRL-1790 cells 
   a *SD = Standard deviation.  
   b The selectivity index is the ratio of IC50 of CRL-1790 normal cells and HCT 116 cancer cells.  
5.2 Combinatorial approach in HCT 116 cells 
The objective of this study was to determine whether N1-acryloylbenzohydrazide derivatives act 
as chemosensitizers and show synergism with 3,5-bis(benzylidene)-4-piperidone or not. For this 
experiment N1-acryloyl-3,4-dimethoxybenzohydrazide 60m was used as a potential 
chemosensitizer. 
As indicated in Table 5.8, the total and live cell count as well as the percentage of live cells were 
measured by an automated cell counter using trypan blue dye. The percentage of live cells is the 
ratio of the live cell count to the total cell count. The time t0 is the reading taken 24 h after seeding 
of HCT 116 cells in T75 flasks and it is considered as control because no solvent vehicle such as 
DMSO was added to the cells. As seen in Table 5.8, the percentage of live cells of different 
concentrations of 60m and 63a were measured either alone or in combination with the reference 
drug 5-FU (3.0 µM) and the negative control (only DMSO). Three independent experiments were 




Mean IC50 (µM) ± *SDa 
against MDA-MB-231 
malignant cells 





5-FU 15.94 ± 1.65 10.84 ± 1.64 0.68 




Table 5.8 : The combinatorial effects of 60m, 63a and 5-FU towards HCT 116 cells after 24 h 
and 48 h 
Compounds 



















t0 1.18 x 10
6 1.10 x 106 92 -- -- -- 
DMSO 1.01 x 10
6 9.20 x 105 91 1.02 x 106 8.75 x 105 86 
Control -- -- -- 2.36 x 10
6 2.25 x 106 95 
5-FU 3 µM 2.83 x 10
5 2.21 x 105 78 1.6 x 105 8.77 x 104 55 
60m 5 µM 6.67 x 10
5 5.87 x 105 88 3.36 x 105 2.52 x 105 75 
60m 10 µM 5.56 x 10
5 3.73 x 105 67 2.51 x 105 1.43 x 105 57 
60m 15 µM 2.95 x 10
5 1.8 x 105 61 2.14 x 105 6.83 x 104 32 
63a 0.1µM 4.45 x 10
5 3.7 x 105 83 2.42 x 105 1.88 x 105 78 
63a 0.2 µM 1.32 x 10
5 9.10 x 104 69 1.78 x 105 9.25 x 104 52 
63a 0.4 µM 1.5 x 10
5 7.2 x 104 48 1.28 x 105 4.15 x 104 32 
60m 5 µM + 63a 0.1µM 7.78 x 10
4 5.45 x 104 70 4.39 x 104 2.76 x 104 63 
60m 10 µM + 63a 0.1µM 6.75 x 10
4 4.59 x 104 68 5.67 x 104 3.34 x 104 59 
60m 15 µM + 63a 0.1µM 5.56 x 10
4 3.06 x 104 55 2.43 x 104 1.1 x 104 45 
60m 5 µM + 63a 0.2 µM 5.56 x 10
4 2.15 x 104 39 6.75 x 104 8.34 x 103 12 
60m 10 µM + 63a 0.2 µM 1.85 x 10
5 5 x 104 27 1.67 x 104 1.72 x 103 10 
60m 15 µM + 63a 0.2 µM 2.78 x 10
4 4.7 x 103 17 1.11 x 103 -- 0 
60m 5 µM + 63a 0.4 µM 3.89 x 10
4 7.3 x 103 19 2.56 x 103 -- 0 
60m 10 µM + 63a 0.4 µM 2.22 x 10
4 2.4 x 103 11 1.67 x103 -- 0 
60m 15 µM + 63a 0.4 µM 2.78 x 10
4 1.39 x 103 5 1.07 x 103 -- 0 
60m 5 µM + 5-FU 3 µM 2.06 x 10
4 1.1 x 104 53 1.48 x104 5.4 x103 37 
60m 10 µM + 5-FU 3 µM 1.1 x 10
3 5.5 x 102 50 1.74 x103 5.56 x102 32 
60m 15 µM + 5-FU 3 µM 1.28 x 10
3 4 x 102 32 1.92 x103 3.84 x103 20 
a The percentage live cells is calculated by the ratio of the live count (cells/ml) and the total cell 





Compounds 60a-m, 61a, 62a-b and 63a were evaluated towards human oral squamous cell 
carcinomas (Ca9-22, HSC-2, HSC-3 and HSC-4). In addition, these compounds were evaluated 
against human non-malignant HGF, HPC and HPLF cells to study the possible selectivity of the 
compounds towards cancer cells. Table 5.9 indicates the CC50 values expressed in µM range. Two 
















Table 5.9 : Evaluation of 60a-m, 61a, 62a-b and 63a against various human carcinoma and normal cell lines 
a The CC50 values are the concentrations of the compounds required to kill 50% of the cells. The values are expressed in µM. Two 
independent experiments were conducted with three replicates in each experiment. 
b The selectivity index (SI) is the ratio of the average CC50 value of the compound towards human normal oral cells to the average CC50 
value for human oral squamous cancer cells. 
Compound 
 
Human oral squamous carcinoma cells (CC50)a Human normal oral cells (CC50)a 
Selectivity 
Index (SI)b 
Ca9-22 HSC-2 HSC-3 HSC-4 Mean HGF HPLF HPC Mean 
60a 33.4 ± 4.0 40.4 ± 4.0 39.2 ± 10.3 70.3 ± 21.7 45.8 ± 16.6 32.1 ± 4.8 37.4 ± 2.0 72.8 ± 0.8 47.4 ± 22.1 1.0 
60b >400 ± 0.0 >400 ± 4.0 385.3 ± 13.7 >400 ± 0.0 >396.3 ± 7.3 222.0 ± 71.9 274.3 ± 154.6 176.7 ± 79.5 224.3 ± 48.9 <0.6 
60c 130.0 ± 2.6 190.0 ± 4.0 237.0 ± 7.9 209.7 ± 18.2 191.7 ± 45.4 257.7 ± 22.6 287.0 ± 16.4 312.3 ± 18.1 285.7 ± 27.4 1.5 
60d 42.4 ± 7.0 45.0 ± 4.0 52.0 ± 6.9 46.6 ± 1.9 46.5 ± 4.0 33.0 ± 1.6 38.5 ± 4.8 72.4 ± 2.0 48.0 ± 21.3 1.0 
60e 53.5 ± 9.2 68.0 ± 4.0 35.7 ± 3.9 87.5 ± 9.1 61.2 ± 22.0 35.4 ± 3.6 57.0 ± 4.5 51.2 ± 63.1 47.9 ± 11.2 0.8 
60f 238.3 ± 39.3 359.7 ± 4.0 >392 ± 13.9 >400 ± 0.0 >347.5 ± 74.8 >379.3 ± 35.8 >400.0 ± 0.0 158.7 ± 73.9 >312.7 ± 113.8 ><0.9 
60g 295.3 ± 24.7 >400 ± 4.0 374.0 ± 25.2 >400 ± 0.0 >367.3 ± 49.5 >400.0 ± 0.0 >391.0 ± 15.6 >400 ± 0.0 397 ± 5.2 ><1.1 
60h 99.4 ± 12 87.4 ± 4.0 73.1 ± 48.5 83.3 ± 10.7 85.8 ± 10.9 76.3 ± 80.8 223.3 ± 21.4 36.6 ± 4.8 112.1 ± 98.4 1.3 
60i 90.1 ± 4.9 136.4 ± 4.0 59.7 ± 20.5 153.7 ± 19.8 110.0 ± 42.9 204.3 ± 169.8 132.8 ± 40.4 20.8 ± 3.3 119.3 ± 92.5 1.1 
60j 247.3 ± 132.7 66.1 ± 4.0 >400.0 ± 0.0 168.0 ± 90.7 >220.4 ± 140.9 44.8 ± 28.9 74.9 ± 58.2 20.8 ± 4.7 46.8 ± 27.1 <0.2 
60k 63.5 ± 4.8 151.7 ± 4.0 114.8 ± 16.8 116.6 ± 22.1 111.7 ± 36.3 92.7 ± 61.4 118.8 ± 51.1 108.8 ± 33.9 106.8 ± 13.2 1.0 
60l 32.2 ± 2.4 46.0 ± 4.0 61.1 ± 6.6 47.2 ± 4.4 46.6 ± 11.8 31.8 ± 4.4 50.3 ± 10.5 67.8 ± 0.3 50.0 ± 18.0 1.1 
60m 310.7 ± 79.9 >400 ± 0.0 >396 ± 6.9 >400 ± 0.0 >376.7 ± 44.0 273.0 ± 33.9 325.7 ± 65.4 206.3 ± 96.7 268.3 ± 59.8 <0.7 
61a >400 ± 0.0 >400 ± 0.0 >400 ± 0.0 >400 ± 0.0 >400 ± 0.0 328.3 ± 67.1 >377.7 ± 38.7 194.3 ± 113.3 >300.1 ± 94.9 ><0.8 
62a >400 ± 0.0 >400 ± 0.0 >400 ± 0.0 >400 ± 0.0 >400 ± 0.0 330.3 ± 60.4 >391.3 ± 15.0 160.8 ± 107.2 >294.1 ± 119.5 ><0.7 
62b >400 ± 0.0 >400 ± 0.0 >400 ± 0.0 >400 ± 0.0 >400 ± 0.0 >400 ± 0.0 >396.0 ± 6.9 273.1 ± 159.3 >356.4 ± 72.1 0.9 








Table 5.10 : Evaluation of  60a, 60d, 60h and 60l against various cancer cell lines (Ramos, NALM-60, CEM, HL-60, JURKAT and 
RAJI) and normal cell lines Hs27 and MCF10A 
 
a The CC50 values are the concentrations of the compounds required to kill 50% of the cells. The values are expressed in µM. 
b SI is the selectivity index, and represents the ratio of the average CC50 value of the compound towards normal cells and the CC50 value for  
each cancer cell line. 
c These values are the average CC50 values of the compounds towards Hs27 and MCF10A cell lines. 
 
 
Compound                                                                          Cancer cell lines (CC50) a Normal cell lines (CC50) a 
 Ramos SIb NALM-60 SIb CEM SIb HL-60 SIb JURKAT SIb RAJI SIb Hs27 MCF10A Avgc 
60a 0.19±0.01 67.63 2.74±0.59 4.69 0.91±0.48 14.12 3.32±0.26 3.87 3.52±0.36 3.65 5.18±0.35 2.48 12.05±0.91 13.65±1.10 12.85 
60d 0.29±0.05 47.10 3.34±0.43 4.09 3.37±0.18 4.05 5.62±0.29 2.43 2.50±0.24 5.46 5.50±1.10 2.48 14.41±0.24 12.89±0.95 13.65 
60h 0.15±0.02 57.74 2.86±0.55 3.03 0.86±0.07 10.07 2.90±0.76 2.99 1.07±0.09 8.09 2.71±0.09 3.20 10.45±0.05 6.87±0.48 8.66 




Compounds 60a, 60d, 60h and 60l were evaluated against six malignant cell lines namely Ramos, 
NALM-60, CEM, HL-60, JURKAT and RAJI  and normal cell lines Hs27 and MCF10A (Table 
5.10). All the compounds are cytotoxic towards both the cancer and non-malignant cells. The 
selectivity index was measured by calculating the ratio of the average CC50 value of the compound 
towards normal skin Hs27 cells and normal breast MCF10A cells by the CC50  value of each 
compound towatds a particular cell line. It can be noted from the Figure 5.2, that all of the 
compounds showed high selectivity towards Ramos lymphocytes. Compound 60l showed more 





















































Figure 5.2 :  The selectivity index figures of 60a, 60d, 60h and 60l against various malignant 




5.3 Studies on mechanisms of action 
5.3.1 Mitochondrial membrane potential 
5.3.1.1 Mitochondrial membrane potential in HCT 116 cells using the TMRE dye 
The TMRE dye accumulates in the mitochondria based on the mitochondrial membrane potential 
(Δψm). In healthy cells, the TMRE dye remains intact within the mitochondria having a normal 
electrochemical gradient which gives rise to fluorescence upon excitation whereas in apoptotic 
cells, because of the changes in Δψm, the TMRE dye moves out of the mitochondria into the cytosol 
resulting in a decrease in the fluorescence signal. CCCP acts as an uncoupling agent resulting in 
intracellular mitochondrial depolarization which remarkably reduces the electrochemical potential 
and thus significantly decreases the fluorescence signal as seen in Figure 5.3. CCCP and 2,4-DNP 
were used as positive controls whereas only DMSO was used as a negative control. It can be seen 
from Figure 5.3, that compound 64e has a significant effect in reducing the MMP as compared to 
the negative control. Both 64a and 64g resulted in a decrease in the MMP with same intensity as 
the standard drug 5-FU. Compound 60m does not show any effect on the MMP. 
 
Figure 5.3 : The effects of cytotoxic agents 60m, 64a, 64e and 64g on the mitochondrial 
membrane potential in HCT 116 cells using the TMRE dye. 
The bar represents means ± SD of three independent experiments with three replicates in each 
experiment. All the results are significantly different from the control (DMSO) based on one-way 




5.3.1.2 Mitochondrial membrane potential in Ramos cells using the JC-1 dye 
Our collaborators evaluated the effect of 60l on the mitochondrial membrane potential of Ramos 
cells using the JC-1 dye as previously described in the literature.78,121 JC-1 tends to form complexes 
such as J-aggregates in the healthy cells having high Δψm resulting in red fluorescence measured 
at 590 nm whereas the apoptotic cells having lower Δψm form monomers producing a green 
fluorescence at 530 nm. The ratio of the JC-1 aggregate to the JC-1 monomers is an indicator of 
overall health of the cells. Thus a decrease in the JC-1 aggregate signifies membrane 
depolarization. 
DMSO was used as the negative control whereas H2O2 was used as the positive control. It was 
observed that H2O2 significantly depolarizes the mitochondrial membrane as compared to the 
untreated cells and DMSO. In this assay, the CC50 concentration of 60l was used. It can be noticed 
from Figure 5.4, that there is nearly 35% of depolarization of 60l at the CC50 concentration whereas 
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Figure 5.4 : The effects of the cytotoxic agent 60l on mitochondrial membrane potential in 
Ramos cells using the JC-1 dye. 
The bar represents means ± SD of three independent experiments with three replicates in each 
experiment. * indicates that the data points are significantly different (p < 0.05) from the control 




5.3.2 Evaluation of reactive oxygen species (ROS) levels in HCT 116 cells 
In this assay, the DCF-DA (2′,7′–dichlorofluorescin diacetate) dye was used to measure ROS 
levels within the cells. DCF-DA is a fluorogenic dye which undergoes deacetylation by esterases 
present in the cells and is converted into a non-fluorescent compound. This non-fluorescent 
compound is oxidized by reactive oxygen species to DCF (2′,7′–dichlorofluorescin). DCF is a 
fluorescent compound which can be detected at excitation at 485 nm and emission at 530 nm. 
DMSO was used as a negative control whereas H2O2 was used as a positive control. An increase 
in the average fluorescence intensity reveals an increase in ROS levels. It can be observed from 
Figure 5.5, that all the compounds caused a 2-4 fold increase in the fluorescence intensity resulting 
in increased ROS levels. All the compounds showed a greater increase in the ROS levels as 
compared to the standard drug 5-FU. HCT 116 cells were treated with the IC50 concentrations of 
the compounds and thus after 48 h incubation, their cell number was reduced to half and therefore 
their fluorescence signal was increased twice as compared to the number of cells treated with 
DMSO.  
 
Figure 5.5 : The effects of cytotoxic agents 60m, 64a, 64e and 64g on ROS levels in HCT 116 
cells using the DCF-DA dye. 
The bar represents means ± SD of three independent experiments were conducted with three 
replicates in each experiment. All the results are significantly different from the control (DMSO) 





CHAPTER 6 : DISCUSSION 
6.1 Design and development of novel cytotoxic agents 
Over the years, our laboratory has mainly focused on the design and development of conjugated 
arylidene ketones as potential cytotoxic agents. These α,β-unsaturated compounds not only  have 
various pharmacological properties but they also show a preferential affinity towards thiols rather 
than amino or hydroxyl groups which are present in nucleic acids, resulting in decreased genotoxic 
side effects.80 Many different compounds possessing α,β-unsaturated keto moieties display 
biological activities; however a major interest is based on one or more of the constituents of a well-
known herbaceous plant called turmeric. Curcumin, isolated from turmeric, is an important lead 
compound exhibiting various biological activities including anticancer properties. Although 
curcumin is safe and effective in vivo, it has emerged as a poor lead compound because of its low 
solubility, metabolic instability and rapid elimination.47 Researchers have made several structural 
modifications of the curcumin moiety such as the 1,5-bis(arylidene)-pentan-2,4-diones which have 
been superceded by compounds containing the 1,5-diaryl-3-oxo-1,4-pentadienyl pharmacophore 
which resulted in the development of a number of curcuminoids as novel cytotoxic agents with 
improved pharmacological activity. 
 
Figure 6.1 : Development of the 3,5-bis(benzylidene)-4-piperidone 63a. 
One such effort was led by Dr. Dimmock and his coworkers to incorporate the 1,5-diaryl-3-oxo-
4-pentadienyl pharmacophore onto various scaffolds. This resulted in the development of 3,5-
bis(benzylidene)-4-piperidone 63a as a lead molecule in our laboratory by mounting the 1,5-diaryl-
3-oxo-1,4-pentadienyl pharmacophore onto a piperidine ring.63 
One of the major drawbacks associated with the use of chemotherapeutic agents is the toxic effect 




hypothesis of sequential cytotoxicity postulated by Dimmock et al. This theory states that an initial 
“chemical insult” may cause greater damage to neoplasms than non-malignant cells. Consequently 
a second interaction with cellular constituents could result in significant tumor-selective toxicity. 
The likelihood exists that the greater the number of alkylating sites that are present, the greater the 
possibility of increased selective toxicity towards tumors.122 In light of this concept, the first 
hypothesis of this project is that attachment of the N1-acyl hydrazides to the piperidyl atom of 3,5-
bis-4-piperidones may increase cytotoxicity.  
In line with the first objective of this project, a series of N1-acyl hydrazides 60a-m were 
synthesized from the esters 58a-m and the hydrazide intermediates 59a-m. Various substituents 
were placed in the aryl ring which have different electronic, hydrophobic and steric properties 
since one objective is to search for correlations between one or more of these parameters and 
cytotoxic properties. The auxiliary binders 60a-m were designed so that they might be able to react 
with different cellular constituents such as thiols (reacting with the α,β-unsaturated keto group), 
amino and hydroxyl groups (interacting with amidic features of 60a-m) as well as aryl and alkyl 
groups (reacting with aryl and alkyl groups of 60a-m). 
 
Figure 6.2 : Possible interactions of 60a-m at auxiliary binding sites. 
3,5-bis(Benzylidene)-4-piperidone 63a is a lead molecule developed in our laboratory as an anti-
neoplastic agent which is cytotoxic towards various types of malignancies including leukemia, 
colon, breast, skin and ovarian tumors. The cytotoxicity displayed towards various neoplasms is 
due to the 1,5-diaryl-3-oxo-1,4-pentadienyl pharmacophore acting at the primary binding site. In 
order to prepare the target compounds 64a-g, the auxiliary binders 60a-m were reacted with 63a 




the interaction of primary and auxiliary binding sites with the malignant and healthy cells might 
be different which may result in greater selectivity and toxicity towards neoplasms.  
 
Figure 6.3 : Design of cytotoxins 64a-g to interact at binding sites A and B.  
6.2 Assessment of the cytotoxicity of novel cytotoxic agents 
After the synthesis of the compounds, the sulforhodamine B assay was used to measure the 
cytotoxic potencies of some of the compounds 60a-m, 61a, 62a-b and 64a-g against malignant 
HCT 116, MCF-7 and MDA-MB-231 cells and non-malignant CRL-1790 cells.  The 
sulforhodamine B dye is used for the quantitative measurement of the protein content. Its main 
principle is that it binds stoichiometrically to the basic amino acids of the cellular proteins under 
acidic conditions such as trichloroacetic acid fixed cells. The exposure to basic conditions such as 
Trizma base results in the solubilization of the dye and the colorimetric end point reflects the total 
protein mass which is proportional to the cell number.  Here, the cytotoxic potencies are described 
in terms of IC50 values, namely the concentration at which cell growth is inhibited by 50%. 
Using the colon cancer cell line HCT 116, all the auxiliary binders 60a-m showed more than 60% 
inhibition at 100 µM concentration. However, only compound 60m showed nearly 47% inhibition 
at 10 µM concentration. The IC50 value of the 3,4-dimethoxy derivative 60m towards HCT 116 
cells was found to be 15.27 µM which is almost 2.4-fold more potent than the unsubstituted analog 
60a (Table 5.2). A noteworthy feature of the results presented in Table 5.1 is the higher potencies 




(2-Cl) > 60d (4-Cl). The addition of a 3-chloro group to 60d to give 60g (3, 4-Cl2) was 
accompanied by an increase in potency. In addition, 60i (3-CH3) > 60j (2-CH3) > 60k (4-CH3). In 
the case of the compounds containing aryl methoxy groups, 60m [3,4(OCH3)2] is 5.4 times more 
potent than 60l (4-OCH3). Hence in the future the 3-methoxy and 3,4,5-trimethoxy analogs should 
be prepared.  
The cytotoxic evaluation of 61a is important for two reasons at least. First, cytotoxicity is displayed 
in the absence of a thiol alkylating group which is present in 60a. Second, the symmetrical 
molecule 61a, which is 1.76 times more potent than 60a, reveals the contribution to cytotoxicity 
of the hydrogen bonding capacity of different groups in 61a as well as the increased potential of 
van der Waals bonding. In the future, a variety of aryl substituents should be placed in one or both 
aryl rings with a view to producing novel potent cytotoxins.  
The data in Table 5.1 reveal that removal of the olefinic double bond of 60a to give 62a and 62b 
was accompanied by a substantial drop in potencies. Thus considering the data obtained using a 
concentration of 100 µM, 62a and 62b have an average of 12.2% of the potency of 60a. This result 
reveals the importance of the α,β-unsaturated keto group in 60a suggesting that interaction of this 
compound with cellular thiols likely contributes significantly to its cytotoxic potency.  
Another observation that may be made on the results portrayed in the Table 5.1 is in regard to 
comparing the cytotoxic potencies of the compounds in series 60 with two established anticancer 
drugs. 5-Fluorouracil was chosen as an agent used in treating colon cancer while melphalan is an 
alkylating agent. Thus the lead compound in the series 60, namely 60m, is more potent than 
melphalan but less cytotoxic than 5-FU.  
The biodata generated in Table 5.2 highlights the IC50 values of the hydrazide analogs 59a and 
59m, as well as the saturated compound 62b, is greater than 100 µM suggesting that their 
corresponding functional groups do not contribute much to cytotoxicity but the acryloyl group in 
series 60 mainly accounts for the cytotoxic potency. For the 3,5-bis(arylidene)-4-piperidones 
derivatives 63, only the unsubstituted compound 63a was examined for its biological activities. 
The other derivatives 63b-f were used for the synthesis of the target compounds 64b-g. The IC50 
value of 3,5-bis (benzylidene)-4-piperidone 63a was found to be 0.365 µM towards HCT 116 cells 




All the target compounds 64a-g, have IC50 values below 4 µM which means at least 50% of HCT 
116 cancer cell growth was inhibited below that concentration (Table 5.3). The “terminal” aryl 
ring is at the end of the side chain on the piperidinyl nitrogen atom. It was found that the compound 
64a which is unsubstituted at the terminal ring was more potent than the 64b which has 3,4-
dimethoxy groups. Overall, 64e possessing a nitro substituent at the para position of the 
benzylidene ring attached directly to the piperidine ring was the most potent compound of series 
64 with the IC50 value of 0.28 µM.  The order of potencies for the substituent at the para position 
of the benzylidene ring attached directly to piperidine ring is as follows: 64e (NO2) > 64g (CH3) > 
64f (OCH3) > 64b (H) > 64c (Cl) > 64d (F). In the case of the reference drugs 5-FU and melphalan, 
the IC50 values were 4.11 µM and 33.2 µM respectively which are similar to the reported values 
by the NCI of 4.55 µM and 30.2 µM, respectively.123 64a-f are in range of 9-117-fold more potent 
than the reference drug melphalan in HCT 116 cells. The IC50 values of 64a-f are 1.1 to 15 times 
lower than the figure for 5-FU.  
As mentioned earlier, in order to overcome the inherent toxic effects associated with current 
chemotherapeutic agents, it is important to ascertain if the compounds in series 60 and 64 exert a 
greater cytotoxicity towards neoplasms than normal cells and therefore these agents were screened 
against the non-malignant colon CRL-1790 cell line. The selectivity index (SI) was calculated by 
dividing the average IC50 values of the compounds towards normal cell lines by the IC50 values of 
the compounds against a specific cancer cell line. All the compounds showed SI figures >1 which 
indicates that they are selectively toxic towards malignant cells. The order of the SI figures 
presented in Table 5.2 is as indicated: 63a (37) > 60m (>6.6) > 60a (>2.70).  The order of the SI 
figures in series 64 (Table 5.3) is as follows: 64e (16.15) > 64g (4.8) > 64a (3.87) > 64f (3.86) > 
64c (3.6) > 64b (3.06) > 64d (2.99). 
Further to understand the relationship between various physicochemical parameters and the 
cytotoxic potencies of target compounds 64b-g, multilinear regression analysis was performed 
using SPSS analysis software.124 Various structural descriptors such as Hansch π, Hammett σ, 
molecular refractivity (MR) and partition coefficient (logP) were used as dependent variables and 
log10IC50 was considered as the independent variable.  
The Hansch π value represents the nature of a substituent towards hydrophilicity and 




drug from its site of administration to its site of action. A positive π value indicates that the 
substituent increases lipophilicity whereas a negative π value means that the aqueous solubility 
will be increased. The Hammett σ values represent the electronic effects of aryl substituents on the 
chemical reactivity of the side chain. The Hammett σ values are calculated for the substituents in 
the meta and para positions of the aryl ring. The molecular refractivity (MR) indicates the sizes of 
different atoms or groups. The logP values refer to the distribution of a solute between hydrophilic 
and hydrophobic solvents. Higher logP values indicates lipophilic nature of a compound whereas 
lower logP values represents its hydrophilicity.125  
The σ, π and MR constants were obtained from the literature.126,127 LogP values of the compounds 
were estimated using Chemdraw Prime 15.0 software.128 Excellent correlations were observed 
between various descriptors and the IC50 values of 64b-g in malignant HCT 116 cells and non-
malignant CRL-170 cells as indicated in equations 1 and 2, respectively. Omitting some 
descriptors did not improve the correlation.  
Log10(𝐼𝐶50 𝐻𝐶𝑇116) = 4.79 ∑ 𝜋 + 1.73 ∑ 𝜎 + 0.07 ∑ 𝑀𝑅 − 3.33𝑙𝑜𝑔𝑃 − 17.93,  
r = 0.986, n = 6                                                                                                                       (1) 
Log10(𝐼𝐶50 𝐶𝑅𝐿−1790) = −22.07 ∑ 𝜋 − 7.66 ∑ 𝜎 − 0.23 ∑ 𝑀𝑅 + 16.03𝑙𝑜𝑔𝑃 + 50.56, 
r = 0.955, n = 6                                                                                                                       (2) 
In these equations, r is the correlation coefficient and n is the number of determinations. Thus in 
future, different analogs with various physicochemical constants can be inserted into equations 1 
and 2 and their cytotoxic potency may be predicted.  
In order to discern whether these compounds showed toxicity towards other malignant cells, the 
auxiliary binders 60a-m were screened against two breast cancer cell lines. MCF-7 cells are 
epithelial estrogen and progesterone positive breast neoplasms whereas MDA-MB-231 is a triple 
negative breast cancer cell line (TNBC), i.e., it is estrogen, progesterone and HER-2 negative. The 
initial screening of 60a-m at 100 µM and 10 µM concentration revealed that only three compounds 
60j, 60k and 60l displayed strong growth inhibiting properties (>50%) at 10 µM towards MCF-7 
cells. Thus the decision was made further to determine their IC50 values and their order of potencies 
are as follows: 60l (3.18 µM) > 60k (5.54 µM) > 60j (9.14 µM). The SI figures of 60l is more than 
31 which is noteworthy and it is 4.5-fold more potent than the reference drug 5-FU. Results showed 




colon CRL-1790 cells. The possible explanation of why only three agents showed inhibition and 
the remaining compounds did not could be that these compounds might be experiencing biphasic 
response, i.e., a compound can stimulate cell growth at lower concentrations but inhibits at higher 
concentration and such expressions are called hormetic responses. Another possible reason can be 
that since the SRB assay is based on quantitative measurement of cellular protein which is directly 
proportional to the cell number, the exact number of healthy cells is difficult to determine. This is 
because the proteins which might be undergoing apoptosis or any other cellular processes, might 
be detected which shows a false high number of living cells.  
The screening of series 60, 61a and 62a-b against MDA-MB-231 cells at 100 µM and 10 µM 
reported in Table 5.6 displayed poor growth-inhibiting properties suggesting that compounds were 
more vulnerable towards estrogen and progesterone positive MCF-7 cell lines than triple negative 
cells. Table 5.7 represents the IC50 values of 5-FU and melphalan which are 15.94 µM and 52.85 
respectively and it was noticed that 5-FU has a greater than 2.8-fold weaker selectivity towards 
malignant cells in comparison to melphalan. 
The hybrid compound 61a formed by condensation of benzohydrazide 59a and N1-acryloyl-
benzohydraizde 60a showed weak inhibition towards all three cancer cell lines (HCT 116, MCF-
7 and MDA-MB-231) at 10 µM concentration and thus further evaluations were not carried out. 
In regard to the saturated compounds 62a-b, as hypothesized, they showed no inhibition at 10 µM 
towards cancer cells HCT 116, MCF-7, MDA-MB-231 as well as to normal cells CRL-1790. The 
probable explanation is that there is no alkylating group in the molecule.  
There is a marked difference between the IC50 values and CC50 values. CC50 values represent the 
cytotoxic concentrations required to kill 50% of the cells whereas IC50 values represent the 
concentration required to inhibit the growth of cells by 50%. Our collaborators in Japan performed 
a cytotoxicity study to examine the effects of 60a-m, 61a, 62a-b and 63a against four human oral 
squamous carcinomas namely Ca9-22, HSC-2, HSC-3 and HSC-4 cells. In addition, they were 
also screened against three human normal cells namely HGF gingival fibroblasts, HPC pulp cells 
and HPLF periodontal ligament fibroblasts. This biodata are presented in Table 5.9.  
The biodata in Table 5.9 indicates that many of the compounds 60b-c, 60f-g, 60i-k, 60m, 61a, 
62a-b, display cytotoxicity towards the carcinomas at CC50 values higher than 100 µM. However, 




CC50 values between 46-86 µM (average CC50 values in µM parenthesis) namely 60a (46), 60d 
(46), 60e (61), 60h (86) and 60l (47). Further, the 3,5-bis(benzylidene)-4-piperidone 63a displayed 
an average CC50 value of <0.46 µM with a selective index of more than 6.8 which is noteworthy. 
Overall, compounds 60a, 60d, 60e, 60h, 60l and 63a exhibited CC50 values less than 100 µM and 
selectivity greater or equal to 1 which indicates that their toxicity towards normal cells is in general 
lower than for the neoplasms. For compounds in series 64, the bioevaluations are yet to be 
performed.  
Further biological evaluation of the auxiliary binders 60a, 60d, 60h and 60l was undertaken to 
investigate their cytotoxic potencies to non-adherent malignant cells. Many leukemic cells are 
spherical and are non-adherent. Our collaborators in El Paso performed the screening of 60a, 60d, 
60h and 60l against six different leukemic cell lines such as Ramos, NALM-60, CEM, HL-60, 
JURKAT and RAJI cells. Moreover, normal human foreskin Hs27 cells and breast cells MCF10A 
were also used to investigate whether these compounds have greater selectivity towards malignant 
cells instead of the non-malignant cells.  
The biodata presented in the Table 5.10 indicates that the auxiliary binders 60a, 60d, 60h and 60l 
displayed high cytotoxic potency towards all the leukemic cells with CC50 values of 5.6 µM or 
less. All four compounds displayed high potency towards Ramos cells in the range of 0.15-0.19 
µM (average CC50 values in µM parenthesis) namely 60h (0.15), 60a (0.18), 60l (0.19) and 60d 
(0.29). It can be clearly observed that all auxiliary binders are highly selective towards Ramos 
cells as compared to other five leukemic cells. The SI figures were obtained by taking the ratio of 
the average CC50 value of the compound towards normal cells and the CC50 value for each cancer 
cell line. Compound 60l has more than 90% selectivity towards Ramos leukemic cells as compared 
to the normal Hs27 and MCF10A cells. The order of selectivity towards Ramos cells are as 
follows: 60l > 60a > 60h > 60d.  
A study was conducted to examine if any of the target compounds 64a-g have drug-like properties. 
Thus these compounds were examined in terms of physicochemical parameters which govern 
intestinal absorption and also predicts their ability to induce toxicity.  The results in Table 6.1, 
reveal that the most desirable ratings appear are 64a, 64b and 64d. Although 64e is the most potent 




metabolites like imines, hydroxylamines, amines in vivo and therefore 64a is the lead molecule 
with the IC50 values of 1.38 µM and SI figure of 3.87.  
Table 6.1 : Evaluation of 63a, 64a-g for drug like properties 
Compound Physicochemical propertiesa Toxicityb 
LogP MW HBA HBD RB TPSA M T I R Ratingsc 
63a 3.36 275.35 2 1 2 29.10 - - - - 10 
64a 4.12 465.55 6 2 7 78.50 - - - - 10 
64b 3.77 525.61 8 2 9 96.97 - - - - 9 
64c 5.12 594.50 8 2 9 96.97 - - - - 8 
64d 4.09 561.59 8 2 9 96.97 - - - - 9 
64e 3.69 615.60 14 2 11 188.62 - - - - 6 
64f 3.88 585.66 10 2 11 115.44 - - - + 6 
64g 4.67 553.66 8 2 9 96.97 - - - - 9 
Drug like 
compound 
<5 <500 <10 <5 <10 <140 - - - - 10 
a The physicochemical properties considered as the logarithm of the partition coefficient (logP), 
molecular weight (MW), the number of hydrogen bond acceptors (HBA), the number of hydrogen 
bond donors (HBD), RB (rotatable bonds) and the total polar surface area (TPSA). These values 
were obtained using the molinspiration Web browser.129  
b The assessment of toxicity was indicated in terms of mutagenicity (M), tumor-indication (T), 
irritant effects (I) and impairment of reproduction (R) using the Osiris Property Explorer tool. The 
toxic effects are indicated as + sign whereas – indicated no possible toxic effects.130 
c A scale of 10 points was used for rating. One point was allocated for each positive result that is 
favourable physical property or the absence of the toxic effects.  
6.3 Combinatorial approach in HCT 116 cells 
A study of whether a representative compound in series 60 is capable of sensitizing HCT 116 colon 
cancer cells to antineoplastic agents was undertaken. The lead compound in series 60 is 60m and 
the cytotoxin chosen is 63a as well as a reference drug 5-FU. The approach taken is to incubate 
the potential chemosensitizer 60m with HCT 116 cells for 24 hours and after this time, the 
cytotoxin is added and the mixture incubated for a further 24 hours. This effect is quantified by 
observing the percentage of live cells at the end of 24 and 48 hours time periods. This raw data is 
portrayed in Table 5.8 (page 74). 





1. The percentage of dead cells was obtained for individual compounds from which is deducted 
the percentage lethality of the solvent DMSO. For example, at the end of 48 hours, the percentage 
of dead cells after incubation of 5 µM of 60m is 86 – 75 or 11 % (Table 5.8, entries 2 and 5) and 
portrayed in Table 6.2, entry 2. 
For example, in the case of 63a (0.1 µM), after 24 hours incubation, the percentage of dead cells 
is 91-83 or 8% (Table 5.8, entries 2 and 8) and presented in Table 6.2, entry 5. 
Table 6.2: The percentage of dead HCT 116 cells after treatment with 5-FU, 60m and 63a for 24 
h and 48 h 
Compound Percentage of dead HCT 116 cells a 
 24 h 48 h 
5-FU 3 µM 13 31 
60m 5 µM 3 11 
60m 10 µM 24 29 
60m 15 µM 30 54 
63a 0.1 µM 8 8 
63a 0.2 µM 22 34 
63a 0.4 µM 43 54 
a The figures of the percentages of the dead cells were calculated by subtracting the percentage of 
live cells of compound from the percentage of DMSO live cells. 
2. The question which now requires resolution is whether chemosensitization takes place with the 
combination of a potential sensitizer (60m) and the cytotoxins 63a and 5-FU. The calculations are 
based on the following biodata generated.  
First consider if the effect was additive, i.e., both 60m and 63a contribute to overall toxicity but 
no chemosensitization has occurred. For example, at the end of 48 h the percentage of dead cells 
after treatment with 60m (5 µM) is 11 (Table 6.2, entry 2). After 24 hours the percentage of dead 
cells treated with 63a (0.1 µM) is 8 (Table 6.2, entry 5). Hence if the cytotoxicity effects are 




However the percentage of dead cells using a combination of 60m (5 µM) and 63a (0.1 µM) is 23 
(86-63, entries 2 and 11, Table 5.8). In this case the difference in percentage of dead cells is not 
significant (Table 6.3, entry 1). On the other hand, when the biodata for a combination of 60m (5 
µM) and 63a (0.2 µM) are considered, sensitization has taken place (Table 6.3, entry 4). 
Table 6.3: Evaluation of the cytotoxic potencies of combinations of 60m with 63a and 5-FU 
Combination 










60m 5 µM + 63a 0.1 µM 11 8 -- 19 23 No 
60m 10 µM + 63a 0.1 µM 29 8 -- 37 27 No 
60m 15 µM + 63a 0.1 µM 54 8 -- 62 42 Yes 
60m 5 µM + 63a 0.2 µM 11 22 -- 33 74 Yes 
60m 10 µM + 63a 0.2 µM 29 22 -- 52 76 Yes 
60m 15 µM + 63a 0.2 µM 54 22 -- 77 100 Yes 
60m 5 µM + 63a 0.4 µM 11 44 -- 55 100 Yes 
60m 10 µM + 63a 0.4 µM 29 44 -- 73 100 Yes 
60m 15 µM + 63a 0.4 µM 54 44 -- 98 100 No 
60m 5 µM + 5-FU 0.3 µM 11 -- 13 24 50 Yes 
60m 10 µM + 5-FU 0.3 µM 29 -- 13 42 54 No 
60m 15 µM + 5-FU 0.3 µM 54 -- 13 67 66 No 
a The figures of the percentages of the dead cells were calculated by subtracting the percentage of 
live cells after treatment of the compounds from the percentage of DMSO live cells. 
 b The calculated values are the sum of either 60m (48 h) and 63a (24 h) or 60m (48 h) and 5-FU 
(24 h). 
 c Actual experimental values. 
d  Paired t-test was performed using GraphPad Prism software at p value < 0.05. 
Thus these experiments have demonstrated a proof of principle that the hydrazide 60m (and 
probably related analogs) under certain conditions sensitizes HCT 116 cells to 63a and 5-FU. In 
the future, this concept of chemosensitization should be developed using other cell lines (including 




6.4 Mechanisms of action 
6.4.1 Mitochondrial membrane potential in HCT 116 cells using the TMRE dye and in 
Ramos cells using JC-1 dye 
During oxidative phosphorylation, transfer of protons occurs via complexes in mitochondria 
resulting in electrochemical gradient across the membrane which generates the mitochondrial 
membrane potential. MMP is directly associated with ATP formation and any alterations is an 
early indicator for the oxidative stress. As mentioned earlier, the changes in MMP occurs due to 
various factors resulting in mitochondrial dysfunction and consequently undesired cell death. High 
Δψm significantly generates ROS. Elevation in the ROS levels leads to alterations in mitochondrial 
membrane permeability which in turn initiates degenerative processes. 105 
Diverse fluorescent lipophilic cationic dyes such as tetramethylrhodamine methyl (TMRM) and 
ethyl (TMRE) ester, Rhodamine 123, DiOC6(3) (3,3′-dihexyloxacarbocyanine iodide), and JC-1  
are used for the determination of the MMP.131 In this project, initial attempt was made to measure 
MMP using JC-1 dye because of its more selectivity than cellular membrane potential but JC-1 
dye precipitated in McCoy’s media (used for HCT 116 cells) after incubation resulting in false-
positive results. Hence, we have used TMRE dye for 60m, 64a, 64e and 64g cytotoxins to monitor 
MMP changes towards HCT 116 cells. The potent cytotoxic agents 60m, 64a, 64e and 64g at its 
IC50 values were examined to determine whether interference with the MMP was one of the ways 
in which bioactivity was achieved. CCCP and 2,4-dinitrophenol depolarizes mitochondria by 
increasing the permeability of protons132 exhibited lowest Δψm. The three target compounds 64a, 
64e and 64g along with 5-FU lowered the MMP. 
Our collaborators have used JC-1 dye for 60l compound. The healthy cells having higher Δψm 
forms J-aggregates and a drop in Δψm results in formation of J-monomers. The collapse of Δψm 
may be due to early stage of apoptosis. The ratio of J-aggregates to J-monomers signals cell health 
or injury. Mitochondrial depolarisation leads to conversion of J-aggregates (healthy cells) to J-
monomers (unhealthy cells).  Compound 60l causes 35% of depolarisation at its CC50 value of 
0.19 µM towards Ramos cells and at its doubled CC50 value more than 65% of depolarisation was 
observed which is noteworthy. It will be interesting to investigate the effect of cytotoxins on 




consumption determination, mitochondrial swelling assay, GST inhibition and activities of the 
electron transport chain complexes. 
6.4.2 Evaluation of reactive oxygen species (ROS) levels in HCT 116 cells 
Reactive oxygen species (ROS) such as hydrogen peroxide (H2O2), hydroxyl ion (OH
-) and 
superoxide anion (O2
-) originate either from intracellular electron transport process in 
mitochondria during aerobic respiration or exogenously by interaction with xenobiotics.133 In 
normal conditions, ROS acts as messengers and plays a crucial role in cell homeostasis via 
regulation of signaling pathways at lower concentrations.134 The supply of nutrients and oxygen 
via angiogenesis allows cancer cells to proliferate resulting in hypermetabolism and higher ROS 
generation in cancer cells as compared to the healthy cells. In cancer cells, mitochondria, 
endoplasmic reticulum and enzymes such as NADPH oxidases contribute to high levels of ROS.135 
To counteract such levels, cancer cells increase their antioxidants activities by several mechanisms 
to maintain the redox levels and incapability to do so leads to oxidative stress inducing cell death.  
Several mechanisms may be responsible for increase in the ROS levels. Any imbalance in 
intracellular ratio of GSSG/GSH or NADPH/NADP+ levels, mitochondrial mutations, electron 
transport dysfunction,135 posttranslational changes of proteins,136 release of cytochrome c and Ca+2 
causing impaired permeability of mitochondrial membranes can damage the cellular 
constituents.137 Excessive production of ROS during oxidative phosphorylation leads to oxidative 
stress which leads to alteration of mitochondrial proteins, damage to DNA and lipid 
peroxidation.135,136 Consequently, the mitochondrial dysfunction results in imbalanced redox 
reactions leading to changes in mitochondrial membrane potential, less ATP formation137, cell 
arrest138 and apoptosis.137 Their alterations can exacerbate neurogenerative disorders such as 
Alzheimer’s and Parkinson diseases as well as musclar dystrophy and brain injury.134 
DCF-DA (2′,7′–dichlorofluorescin diacetate) dye was used to measure ROS levels however this 
study did not detect different types of ROS (H2O2, OH
-) species. The main purpose was to study 
the effects of cytotoxins on ROS. About a 2-4 fold increase in ROS was measured after treatment 
of HCT 116 cells with IC50 concentrations of 60m, 64a, 64e, and 64g along with reference drug 
5-FU. The order of intensities inducing elevation of ROS levels is as follows: 64e > 64a > 64g > 




by increasing ROS levels. It would be also interesting to determine the antioxidant activity of these 
cytotoxins. 
6.5 Future work 
The first step in expanding the project is to determine structure-activity relationships of the target 
compounds and correlate the sizes of the atoms and nature of functional groups for better alignment 
with the cellular constituents. Moreover, ex vitro stability studies which mimic the in vivo 
environment should be carried out to examine any degradation of the target compounds, if any. If 
the compounds are degraded, then the possible metabolites should be identified by such techniques 
as LC-MS. It will be also interesting to investigate their mechanisms of actions and their effect on 
signaling pathways. 
The next step can be the design and synthesis of varied analogs of lead molecule 64a by 
incorporating various substituents with different electronic parameters onto the benzylidene ring 
attached to the piperidone ring.  Additionally, a strong structure-activity relationship may be 
established. Further, it may be important to know whether these analogs act by the same 
mechanisms. The results showed that the target compounds have some effect on mitochondria; 
however, the exact mechanisms are yet to be addressed. Different mechanisms may be responsible 
for apoptosis such as mitochondrial swelling, regulation of GST/GSH levels, changes in an 
electron respiratory complex, damaging mitochondrial DNA and increase in intracellular ROS 
levels. Thus, it will be interesting to investigate the mode of action studies for these compounds.  
Later after confirming the activity of the lead cytotoxin 64a in vitro, further evaluation can be 






CHAPTER 7 : CONCLUSIONS 
A series of novel N1-acylhydrazides 64a-g as potential cytotoxic agents having 1,5-diaryl-3-oxo-
1,4-pentadienyl and N1-acylhydrazides pharmacophores were developed. The auxiliary binder N1-
acryloyl-3,4-dimethoxylbenzohydrazide 60m is the lead compound in series 60 which inhibits the 
proliferation of HCT 116 cells with an IC50 value of 15.3 µM. Moreover, 60m is highly selective 
towards some colon cancer cells with a SI value of more than 6.55.  The combinatorial study 
revealed that the auxiliary binder 60m acts as a chemosensitizer to 3,5-bis(benzylidene)-4-
piperidone 63a as well as the reference drug 5-FU towards colon HCT 116 cancer cells. 
The auxiliary binders 60j, 60k and 60l inhibited the proliferation of MCF-7 breast cells and 60l 
was found to be the most potent compound with an IC50 value of 3.18 µM and a SI value > 31. 
These auxiliary binders showed weak growth inhibition at 10 µM concentration towards MDA-
MB-231 cells. This means that these compounds are more susceptible in the presence of estrogen 
and progesterone environments of MCF-7 cancer cells than in triple negative MDA-MB-231 breast 
malignant cells. The selectivity of these cytotoxic agents towards MCF-7 is quite interesting and 
further investigations in regard to its mode of action should be carried out.  
The auxiliary binders 60a-m, 61a, 62a-b and 63a were evaluated against a number of oral 
carcinomas as well as normal cell lines by our collaborators in Japan. Although only a few agents 
show some activity, compound 63a displayed noticeable results with good selectivity towards oral 
malignant cells than non-malignant cells. Another study was conducted by our collaborators in El 
Paso who found some remarkable results when these auxiliary binders were screened against 
various leukemic cell lines as well as normal cell lines. The auxiliary binders 60a, 60d, 60h and 
60l not only killed 50 % of cancer cells at the average CC50 values less than 0.3 µM but were also 
highly selective towards Ramos leukemic cells. In particular, compound 60l showed more than 90 
% selectivity. Thus compound 60l was further investigated for its mode of action of causing cell 
death and a mitochondrial membrane potential (MMP) study was conducted by our collaborators 
using the JC-1 dye. The results showed that by employing twice the CC50 concentration, there is 
2-fold increase in the mitochondrial depolarization.  
A series of novel cytotoxins were developed and compound 64e possessing a nitro substitution at 




terminal ring was the most potent compound (IC50 = 0.28 µM) against HCT 116 cancer cells; 
however compound 64a emerged as the lead cytotoxin as there is a possibility that nitro groups 
may form toxic metabolites like imines, hydroxylamines and amines in vivo. In general, all the 
target compounds were selectively toxic towards colon HCT 116 malignant cells than CRL-1790 
non-malignant cells. The collapse of the mitochondrial membrane potential in HCT 116 cells by 
64a, 64e and 64g confirmed that mitochondria are an important target involved in cell death. 
Compounds 60m, 64a, 64e and 64g resulted in a 2-4 fold increase of ROS levels, however, the 














Table 1 indicates one-way ANOVA with Dunnett’s multiple comparison post-hoc analysis of each 
compound when compared to DMSO to study the effect on MMP in HCT 116 cells using the 
TMRE dye.  
Dunnett's multiple comparisons 
test 
Mean Diff. 95% CI of diff. Significant p 
<0.05 
DMSO vs. 5-FU -4136 -6645 to -1626 Yes 
DMSO vs. CCCP 8734 6224 to 11243 Yes 
DMSO vs. 2,4-DNP 4417 1908 to 6927 Yes 
DMSO vs. 60m -10715 -13224 to -8205 Yes 
DMSO vs. 64a -3530 -6040 to -1020 Yes 
DMSO vs. 64e 3682 1173 to 6192 Yes 
DMSO vs. 64g -3225 -5734 to -715.2 Yes 
All the values were significantly different with a p value < 0.05. The GraphPad Prism program 
was used for the statistical analysis.139 
Appendix B 
Table 2 indicates one-way ANOVA with Dunnett’s multiple comparison post-hoc analysis of 60l 
when compared to DMSO to study the effect on MMP in Ramos cells for JC-1 aggregates. 
Dunnett's multiple comparisons 
test 
Mean Diff. 95% CI of diff. Significant p 
<0.05 
DMSO vs. 60l CC50 14.10 3.267 to 24.93 Yes 
DMSO vs. 60l 2xCC50 47.30 36.47 to 58.13 Yes 
DMSO vs. untreated cells -2.067 -12.90 to 8.766 No 
DMSO vs. H2O2 80.40 69.57 to 91.23 Yes 
All the values were significantly different with a p value < 0.05 except for the values of DMSO 





Table 3 indicates one-way ANOVA with Dunnett’s multiple comparison post-hoc analysis of 60l 
when compared to DMSO to study the effect on MMP in Ramos cells for JC-1 monomers.  
Dunnett's multiple comparisons test Mean Diff. 95% CI of diff. Significant p 
<0.05 
DMSO vs. 60l CC50 -14.10 -24.93 to -3.267 Yes 
DMSO vs. 60l 2xCC50 -47.30 -58.13 to -36.47 Yes 
DMSO vs. untreated cells  2.067 - 8.766 to 12.90  No 
DMSO vs. H2O2 -80.40 -91.23 to -69.57  Yes 
All the values were significantly different with a p value < 0.05 except for the values of DMSO 
and the untreated cells. The GraphPad Prism program was used for the statistical analysis.139 
Appendix D 
Table 4 indicates one-way ANOVA with Dunnett’s multiple comparison post-hoc analysis of each 
compound when compared to DMSO to study the effect of ROS levels in HCT 116 cells. 
Dunnett's multiple comparisons test Mean Diff. 95% CI of diff. Significant p 
<0.05 
DMSO vs. H2O2 -18500 -20099 to -16901 Yes 
DMSO vs. 5-FU -3977 -5576 to -2378 Yes 
DMSO vs. 60m -6148 -7747 to -4549 Yes 
DMSO vs. 64a -7863 -9461 to -6264 Yes 
DMSO vs. 64e -14071 -15670 to -12472 Yes 
DMSO vs. 64g -5940 -7539 to -4341 Yes 
All the values were significantly different with a p value < 0.05. The GraphPad Prism program 
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